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Abstract 
 
Homeobox genes are known to be active during development and they are turned off after the 
early stages of developmental life. The HLXB9/MNX1 gene is a homeobox gene localized on 
human chromosome 7 and is involved in the development of pancreas and the nervous system.  
However, some leukaemia research groups have reported an over-expression of HLXB9 in 
leukaemia patients who carry the t(7;12) and in the GDM-1 cell line that carries the t(6;7). The 
mechanisms of leukaemogenesis in t(7;12) patients are still unclear. The t(7;12) is one of the 
recurrent cytogenetic abnormalities that is associated with infant acute myeloid leukaemia 
(AML) patients and has been linked to poor prognosis. The aim of this study was (i) to 
determine the involvement of HLXB9 in cell lines known to express this gene at the transcript 
level and (ii) to investigate the position on HLXB9 in AML patients with abnormalities of 
chromosome 7. This aim was achieved through a series of experiments involving the use of 
both conventional and molecular cytogenetics.   
In the first place, the chromosomal abnormalities in leukaemia and lymphoma cell lines 
(GDM-1, K562 and Pfeiffer) have been analysed using G-banding and Multiplex FISH (M-
FISH) techniques. 
Furthermore, FISH using whole chromosome painting technique was performed on 7 AML 
patients to investigate chromosome 7 rearrangements.   
Thirdly, the involvement of the homeobox gene HLXB9 has been investigated in the acute 
myeloid leukaemia (AML) derived cell line GDM-1 and in 4 AML patients. Fluorescence in 
situ hybridization (FISH) analysis was carried out using a specific probe for the HLXB9 gene 
on the AML patients in single and dual colour FISH in combination with an additional probe 
distal to HLXB9 on the GDM-1 cell line. FISH analysis showed no involvement of the HLXB9 
ii 
 
gene in any rearrangement or breaks at chromosomal level on the AML cell line (GDM-1) and 
AML patients. Nevertheless, a breakpoint either proximal or distal to HLXB9 has been 
identified. 
In particular, the breakpoint in the GDM-1 cell line has been confirmed on between the two 
probes used. This thesis poses the basis for further studies to investigate the mechanisms of 
oncogenesis in leukaemias with over-expression of HLXB9 in relation to possible breakage of 
chromosome 7 in the vicinity of the gene.  
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1. Introduction  
 
1.1 Normal haematopoiesis and leukaemia 
 
Haematopoiesis is the creation of all types of the blood cells. Blood cells are produced 
primarily during early embryogenesis in the yolk sac (embryonic haemopoiesis) and in liver 
and spleen at later stages. During adult life, haemopoiesis is a continuous and active process 
in the bone marrow (Ebdon et al., 2010).  
Stem cells play a significant role in haemopoiesis. These cells are able of self-renewal and 
differentiate into multiple cell lines depending on physiological needs (Ebdon et al., 2010). 
(Figure 1.1).   
All various types of blood cells are created from one type of blood cells that is called the 
haematopoietic stem cell (HSC). The HSC cells divide to generate more stem cells or 
differentiate into myeloid or lymphoid progenitors (Hoang, 2004).  
Some leukaemia cases are caused by genetic mutations during blood stem cells production in 
the foetus (Greaves et al., 2003). Scientists believe that they are the main cellular targets for 
leukaemogenesis in haemopoiesis and in addition, dysregulation in the normal blood cell 
formation system could result in haematological disorders. 
Apoptosis is another important element that affects leukaemogenesis. Apoptosis maintains the 
blood homeostasis and keeps the population of blood cells in suitable numbers (Knowles et 
al., 2005).  
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Several studies suggest that certain vital genes, such as the HOX Genes that control cell 
division, proliferation and apoptosis are defective. As a result, surviving abnormal cells can 
constitute a clone of defective cells that can initiate the development of leukaemia (Greaves et 
al., 2003).  
Chromosomal translocations are likely to happen at a very early stage during embryo 
development in some cases of childhood leukaemia (Greaves et al., 2003). These genetic 
abnormalities produce a pre-leukaemia or malignant cell clone, which only turns into 
leukaemia cells that could be activated later in life by additional mutations, such as gene 
deletions or external factors. This hypothesis assumed that leukaemia develops under a 
multistep mechanism (Figure 1.2) (Greaves, 2007; Knudson, 1971). 
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Blood 
Bone  
marrow 
Figure 1.1: Schematic representation shows haemopoiesis process with all the precursors in 
the bone marrow and the mature blood elements in the peripheral blood (Morrell, 2009). 
 
 
 
 
5 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Normal chromosome  Primary mutation Frequent additional 
mutation such deletion 
Chromosome with inherited mutation such 
in a tumour suppressor gene 
Additional mutation during life such a deletion 
Figure 1.2: Schematic representation of the two hits hypothesis in cancer (Knudson, 1971) that required 
two genetic changes on both alle to progress to cancer. 
Tumour 
initiation  
Tumour initiation  
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1.2 Leukaemia 
 
1.2.1 Definition 
Leukaemia is the cancer of bone marrow and blood. It is defined as an increase or decrease in 
the number of immature white blood cells in the blood and bone marrow depending on which 
stage of the cell differentiation is blocked. The cancer cells cannot respond to normal control 
mechanisms and they continue their abnormal cell division. As a result, an abnormal white 
blood cell count is found in blood and bone marrow of the leukaemia patients. The cancerous 
cells are formed basically in the bone marrow, and then move into the bloodstream (Ludwig, 
2009). It is thought leukaemia is a result of haematopoiesis dysregulation of the blood stem 
cell.  
 
1.2.2 Classification 
Leukaemia is classified into two groups depending on the cell origin:  myelogenous or 
lymphocytic both of which can be acute or chronic (Ludwig , 2009). Thus there are four 
major types of leukaemia: acute myelogenous leukaemia (AML), acute lymphocytic 
leukaemia (ALL), chronic myelogenous leukaemia (CML) and chronic lymphocytic 
leukaemia (CLL) (Ludwig, 2009). 
 
Initially, classification systems of acute and chronic leukaemia relied on cytomorphological 
and cytochemical findings. Moreover, current classification systems of acute and chronic 
leukaemias mainly depend on cytomorphology, cytochemistry, immunophenotyping, 
immunogenetics and molecular cytogenetics (Szczepanski et al., 2003). 
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The French-American-British (FAB) group that was established in 1976 has proposed a 
classification of leukaemia based on morphological and cytochemical features. Two main 
forms of acute leukaemia have been standardized by that organization: acute myeloid 
leukaemia (AML) and acute lymphoblastic leukaemia (ALL) (Bennett et al., 1976). 
Modern classification systems have integrated immunophenotyping for a more accurate 
description of the haematopoietic lineage and differentiation stage of different kinds of 
leukaemias. Actually, immunophenotyping is essential for classification of lymphoid 
malignancies and also critical for the characterization of several subtypes of AML 
(Szczepanski et al., 2003).The present World Health Organization classification (WHO) of 
leukaemia and lymphomas includes cytogenetic and molecular characteristics (Szczepanski et 
al., 2003). 
Lymphoid Leukaemia 
 
Myeloid Leukaemia 
 
 
 
L1 Small monotonous lymphocytes. 
 
L2 Mixed L1- and L3-type 
lymphocytes. 
 
L3 Large homogeneous blast cells. 
 
 
 
 
 
 
M0 Undifferentiated acute myeloblastic 
leukaemia. 
M1 Myeloblasts without maturation. 
M2 Myeloblasts with maturation. 
M3 Hypergranular promyelocytic 
leukemia. 
M4 Myelomonocytic leukocytes. 
M5 Monocytic, subtype. 
M6 Erythroleukemia. 
M7 Megakaryocytic leukaemia 
Pleomorphic undifferentiated cells with 
cytoplasmic blebs. 
Table 1.1: FAB-Classification, The French-American-British (FAB) group that was established in 
1976 has proposed a classification of leukaemia based on morphological and cytochemical features.  
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1.2.3 Childhood leukaemia 
Leukaemia forms one-third of all childhood cancer in Great Britain and more than 400 cases 
of childhood leukaemia are diagnosed every year (Swerdlow et al., 2001). 
The most common type of leukaemia in children is Acute Lymphoblastic Leukaemia (ALL), 
which represents 12% of all leukaemia and 80% in childhood leukaemia (Redaelli, 2005). 
According to the Leukaemia and Lymphoma Research Organization, ALL is the most 
common in children of 2- 4 years old and males have a higher risk of being affected. In 
contrast, AML is less common in children (Table1.2).  However, one out of 2000 children has 
a risk to have acute leukaemia under the age of 15 years (Kersey, 1997).   
  
Acute leukaemia Chronic leukaemia 
 
Acute lymphoblastic (lymphoid) leukaemia 
(ALL): 80% of cases of childhood leukaemia 
 
Chronic myeloid leukaemia (CML): less 
than 5% of childhood leukaemia 
 
Acute myeloid leukaemia (AML): most of 
the remaining cases 17% -15% 
 
Chronic lymphoblastic leukaemia (CLL): 
is unknown in children 
Table 1.2: The most common types of leukaemia in childhood according to children with 
cancer organization, 2012,UK. 
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1.3 Chromosomes and genetic aberrations in leukaemia 
 
1.3.1 Normal human karyotype 
Chromosomes are located in the nuclei of eukaryote cells and contain the inherited materials 
(DNA) that carry the genetic instructions for living organisms (Strachan and Read, 2004).    
A normal human cell contains 46 chromosomes that are divided into 23 pairs; 22 pairs of 
autosome (non–sex) chromosomes and one pair of sex chromosome (XX or XY) for female 
and male respectively (International System for Human Cytogenetic Nomenclature-ISCN, 
2009). The homologous chromosomes (each chromosome in one pair) come from each 
parent.  
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Figure 1.3: (A) Schematic drawing of metaphase human chromosome. (B) An example of a 
male normal human karyotype including 22 autosome and a sex pair of (XY) (Wippold and 
Perry, 2007). 
1.3.2 Chromosomal abnormalities 
 Aberrations in the number and structure of chromosomes are frequently found in tumours 
(Macdonald and Ford, 1997). A single genetic change is rarely sufficient for the development 
of a malignant tumour, and evidence suggests a multiple process of accumulating genetic 
alterations (Croce, 2008). The International System for Human Cytogenetic Nomenclature 
(ISCN) defines how abnormal and normal chromosomes are described (2009), and examples 
of terminology of abnormalities that are common as described below, so that chromosome 
bands are identified by a suggested terminology.  
Various chromosomal abnormalities have been associated with haematological disorders 
(Chetverina and Chetverin, 2010) as seen in (Table1.4). 
1.3.2.1 Numerical abnormalities 
Numerical chromosomal aberrations are involved in any changes in chromosome numbers in 
a karyotype. Numerical chromosomal abnormalities can be divided into main groups 
according to Rooney (2001): 
(i) Polyploidy that referred to the gain of whole sets of chromosomes, such as cells with 
69 chromosomes (triploid) or 92 chromosomes (tetraploid). 
(ii) Aneuploidy (the most common numerical abnormalities) is the l loss or gain of one or 
a few copies of chromosomes.  Common examples of aneuploidy are monosomy 
(-) chromosome and trisomy (+) chromosome (Rooney, 2001).   
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1.3.2.2 Structural chromosomal abnormalities and possible mechanisms of 
leukaemogenesis 
Chromosomal Deletion 
Chromosomal deletions involve the loss of a segment of a chromosome. The deletions are 
divided into three main types: terminal, interstitial and microdeletions. Both types of 
deletions (terminal and interstitial) have been described in detail in chapter 4 of this thesis. 
Microdeletions are very small interstitial deletions (less than 3 MB of DNA in size) and 
approximately include one single band within a chromosome only. The chromosomal 
microdeletions are not detectable by conventional cytogenetic method (G-banding) and can 
only be detected by FISH using a specific locus probe (Rooney, 2001).There are two possible 
mechanisms of leukaemogenesis associated with chromosomal deletions (i) gene dosage 
effect haploinsufficiency and (ii) via tumour suppressor genes. 
 Haploinsufficiency 
Abnormalities of the human Genome are various types such as gain, loss or re-orientation of 
DNA region contain dosage-sensitive genes. One group of genomic disorder occurs by 
hemizygous deletions causing a haploinsufficiency (lose of a gene copy) of a single or several 
genes (O’Driscoll, 2008). 
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Tumour suppressor genes 
Tumour suppressor genes (TSG) are present in normal cells and control cell division, DNA 
repair and apoptosis. Mutations in tumour suppressor genes are a result of uncontrolled cell 
growth which can cause a cancer. Numerous tumour suppressor genes have been identified in 
cancer, for example TP53 (p53) that is altered in more than 50% of human cancers 
(Komarova, 2003), RB1 (retinoblastoma susceptibility gene) and BRCA1 and BRCA2 that are 
mutated in familial breast cancer (Knudson, 2001) and APC that is involved in sporadic 
colorectal cancer (Nishisho et al., 1991). The two copies of the gene have to be inactivated to 
develop a cancer (Knudson, 2001) (Figure 1.2). 
Chromosomal Inversions 
Chromosomal inversions involve two breakpoints within a chromosome resulting in inverting 
the chromosomal segment between these two breaks, and inserting it back to its same 
position. The inversion is paracentric in the case of both breakpoints on the same arm and 
pericentric in case of two breakpoints in different arms (Rooney, 2001). The most common 
type of inversion in AML is inversion 16 inv(16) (Table 1.4). 
Chromosomal insertions 
Insertions occur when a segment of a chromosome is removed and inserted at a different 
point on that chromosome or different chromosome (Rooney, 2001). 
Chromosomal duplication 
Duplications happen when a segment within a chromosome is duplicated next to itself. Direct 
duplication is when the chromosomal segment keeps the original orientation and inverted 
duplication is when the segment has altered its orientation (Rooney, 2001). 
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Ring chromosomes 
A ring chromosome is formed when a deletion takes place in both arms of a chromosome 
resulting in connecting the two ends of that chromosome to each other (Rooney, 2001). 
Philadelphia chromosome is an example of the ring chromosome and it is a result of t(9;22) 
in AML. 
Marker chromosomes 
Marker chromosome is a chromosome that is unable to be identified within the karyotype 
(Rooney, 2001). 
Chromosomal translocations  
Chromosomal translocations, whether balanced or unbalanced, are described in detail in 
chapter 4 of this thesis. This section will focus more on the possible mechanisms of 
leukaemogenesis arising from chromosomal translocations. According to Rabbitts (1994), 
chromosomal translocations contribute to two main consequences, such as the creation of a 
fusion gene, when within a gene on each chromosome, breaks occur, that leads to a chimeric 
protein being encoded. The other consequence is when the juxtaposition of a coding region 
from a gene to the promoter of another gene induces ectopic or aberrant expression of a 
proto-oncogene.  
 
Formation of fusion gene with production of a chimeric protein 
The first human chromosomal aberration that was linked to a human disease specifically was 
the Philadelphia (Ph) chromosome, and this fusion gene has been revealed in over 95% of 
CML cases (Dreazen et al., 1987; Rowley, 1980; Nowell and Hungerford, 1960). The fusion 
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gene BCR-ABL is formed by t(9;22) as chromosome 9 is translocated to chromosome 22. 
This translocation position (ABL) oncogene that localize at chromosome 9 beside the 
breakpoint cluster region (BCR) of Philadelphia gene on chromosome 22 results in tyrosine 
kinase activation (Rabbitts, 1994). 
Although tyrosine kinases are targets of AML associated chromosomal translocations, other 
common targets are dysregulation of transcription factors, which has a role that is critical 
during haematopoiesis. This is shown by over 12 chromosomal translocations that target 
subunits within the core binding factor (CBF), where CBFB and RUNX1 (AML1) form the 
composition of a heterodimeric transcription  
The loss of function of CBF is due to chromosomal translocations, for example, 
translocations include t(12;21) (Romana et al., 1995), inv(16) (Liu et al., 1993) and t(8;21) 
(Erickson et al., 1992), which led to expression of ETV6/AML1, CBFB/MYH11 and 
AML1/ETO fusion proteins, (Barba et al., 1993; Golub et al., 1999).  
HOX genes family members are reported to be expressed persistently as a result of 
chromosomal translocations in haematological malignancies. For example, several HOX 
genes have been fused to NUB98 such as HOXA 9 gene (Borrow et al., 1996), HOXD13 
(Egilmez et al., 1998; La Starza et al., 2003), HOXA11 (Fujino et al., 2002; Taketani et al., 
2002). 
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Chromosome 
abnormality 
Disease Frequency Fusion gene 
t(8;21)(q22;q22) AML-M2 18% (30%) AML1-ETO 
t(15;17)(q21-q11-22) AML-M3 10% (98%) PML-RARα 
t(11;17)(q23,q21) AML-M3 Rare PLZF- RARα 
Inv(16) or t(16;16) AML-M4E0 8  (  100%) CBFβ-MYH11 
t(9;11)(p22;q23) AML-M4 11% (30%) MLL-AF9 
t(6;11) 
t(10;11) 
t(11;17) 
t(11;19) 
t(4;11) 
AML-M5    23 
abnormalities are 
detected in  35% of 
all 
AML-M5 
ALL-AF6/AF6q21 
MLL-AF10;CALM-AF10 
MLL-AF17/AF17q25 
MLL-ENL/ENL/EEN 
MLL-AF4 
t(6;9)(p23;q34) AML-M1,M2, M4, 
M5 
1% DEK-CAN 
t(16;21)(p11;p22) AML ‹    TLS(FUS)-ERG 
t(16;21)(p24;p22) t-AML, MDS ‹    AML1-MTG16 
t(3;21) AML ‹    AML1-EV11 
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AML1-EPA 
AML1-MDS1 
t(7;11)(p15;p15) AML-M2, M4 ‹     NUP98-HOXA9 
t(1;11)(q23;p15) AML-M2  NUP98-PMX1 
t(8;16)(p11;p13) AML-M4, M5 ‹    MOZ-GBP 
Inv(8)(p11,p13) AML-M0, M1, M5 ‹     MOZ-TIF2 
t(8;22)(p11;p13) AML-M5 ‹    MOZ-P300 
t(12;22)(p13;p23) AML-M4, CML ‹    TEL-MN1 
t(5;12)(q33;p12) CMMOL 2-5% TEL-PDGFRβ 
t(1;19)(q23;p13) AML-M7 ‹    OTT-MAL 
 
 
 
 
 
 
 
 
 
Table 1.3: The most common fusion genes in acute myeloid leukaemia and myeloidsplastic 
disorder resulting from chromosomal translocations as described by Rego (Rego, 2002). 
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Proto-oncogenes: Aberrant Expression  
According to Kuppers and Dalla-Favera (Kuppers and Dalla-Favera, 2001) in their study of 
lymphomas and lymphoid leukaemia, activation of proto-oncogenes is often a result of 
chromosomal translocations, which involves coding regions becoming associated with 
immunoglobulin or T-cell receptor gene-regulatory elements, which results in these proto-
oncogenes being expressed inappropriately. In Burkitt's lymphoma cases, around 90% reveal 
t(8;14)(q24;q32) that places the MYC proto-oncogene in juxtaposition to the immunoglobulin 
heavy chain gene promoter and enhancer (IgH). In another study by Showe et al. (1985), the 
findings revealed that MYC could also be involved with t(2;8) and t(8;22) variant 
translocations, as these translocate into the immunoglobulin κ and λ light chain loci. 
However, the coding region is not altered for MYC in these translocations, and suggests that 
over-expression or under-expression could contribute to its oncogenic activity (Rawat, 2006).  
According to Rawat (2006) research into the role of malignant transformation in myeloid 
leukaemia has not yet revealed that chromosomal translocation could induce ectopic and 
aberrant expression of a proto-oncogene, which contrasts with research into lymphoblastic 
leukaemia and lymphomagenesis. Point mutations or aberrant expression of proto-oncogenes 
could contribute to the development of leukaemia, as in animal models, some fusion genes 
fail to induce leukaemia, and over 50% of cases with acute myeloid leukaemia lack obvious 
cytogenetic abnormalities.  
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Chromosomal abnormality Genes involved Frequency in given leukaemia type, % 
AML ALL CML CLL 
 
t(8;21)(q22;q22) 
inv(16)(p13q22)/t(16;16)(p13;q22) 
t(15;17)(q22;q21) 
t(11q23) 
del(5q) 
del(7q) 
Trisomy of 8th chromosome 
t(9;22)(q34;q11.2) 
t(12;21)(p13;q22) 
t(1;19)(q23;p13.3) 
t(17;19)(q22;p13) 
t(8;14), t(2;8), t(8;22) 
Trisomy 12 
del(13q14) 
del(11q22-q23) 
del(17p13) 
del(6q21) 
 
 
 
 
 
AML1-ETO 
 
CBFB-MYH11 
 
PML-RARA 
 
MLL 
 
 
 
 
 
 
BCR-ABL1 
 
TEL-AML1 
 
TCF3-PBX1 
 
TCF3-HLF 
 
MYC 
 
 
 
 
 
 
TP53 
 
 
5-12 
 
3-10 
 
6-15 
 
5-8 
1-11 
1-7 
 
3-10 
 
1-2 
 
 
 
 
 
 
 
 
7-10 
 
 
 
 
 
 
5-25 
 
10-25 
 
2-5 
 
1 
 
1-2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
90-95 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13 
 
45 
 
15 
 
6 
 
5 
 
 
 
Table 1.4: A list of common chromosomal abnormalities in haematological malignancies. 
AML (acute myeloid leukaemia); ALL (acute lymphoid leukaemia); CML (chronic myeloid 
leukaemia); CLL (chronic lymphoid leukaemia) (Chetverina and Chetverin, 2010). 
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1.4 The role of homeobox genes in leukaemia 
 
1.4.1 Homeobox genes 
Homeobox genes are involved significantly in embryonic development, cell differentiation, 
proliferation, apoptosis (Cillo et al., 1999; Tupler et al., 2001), as well as normal and 
malignant haematopoiesis (Bach et al., 2010). These genes are found in the genomes of all 
animals, plants and fungi and are extremely conserved during evolution (Lappin et al., 2006).  
Homeobox genes are distributed in four paralogous clusters on chromosomes 2, 7, 12 and 17 
(Borrow et al., 1996). 
Although now known in most eukaryotic species, it was during the 1980s that the homeobox 
(HB) was revealed as a sequence motif shared by drosophila homeotic genes (HOM-C 
complex), and was shown to contribute to embryonic differentiation along the anterior-
posterior (ap) axis (Stein et al., 1996). Tupler et al. (2001) suggested that around 200 
homeobox genes are contained within the human genome, but only 39 were shown to be part 
of the HOX family. The constitution of homeobox genes is characterised as a gene family 
with a 183-nucleotide sequence that is highly conserved that encodes a 61-amino acid 
domain, known as the homeodomain (HD), which has DNA binding activity that is sequence 
specific, and is related structurally to the helix-turn-helix motif of prokaryotic DNA-binding 
(Buske and Humphries, 2000).  
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1.4.2 Leukaemic and normal haematopoietic cells: HOX gene expression  
In mammalian adult normal and neoplastic tissues, as well as embryonic tissue, HOX genes 
are expressed, which has been widely reported in research studies, such as haematopoietic 
cells (Antonchuk et al., 2002; Argiropoulos and Humphries, 2007), human colonic mucosa 
(Wang et al., 2001), kidney (Barba et al., 1993) and normal and neoplastic skin (Care et al., 
1996). Findings from these studies show that HOX gene expression is very different when 
comparing early progenitors and more mature differentiated hematopoietic cells, and is also 
strictly regulated in normal haematopoiesis. According to Buske and Humphries (2000), in 
early CD34+ haematopoietic progenitors, HOX genes of the A, B and C cluster are expressed, 
but there is no HOXD gene transcription in this progenitor pool. However, in the more mature 
CD34- compartment, some HOX genes of A, B and C clusters are substantially down-
regulated or absent (Lawrence et al., 1996). 
Knockout mouse models have been used to investigate the function of HOX genes in 
haematopoiesis. Perkins et al. (1990) found when studying mice, over expression of 
HOXB8/IL-3 resulted in an aggressive transplantable leukaemia, which contrasted to the 
results when transplanting mice with only IL-3. Nakamura et al. (1996) found that in the 
BXH-2 mouse line, over expression of HOXA9 and HOXA7 can initiate AML.  
Studies of patients with acute myeloid leukaemia (AML) found that leukemic blasts revealed 
an aberrant pattern of HOXA10 expression, which suggests that dysregulated HOX gene 
expression could be an overall feature of this malignancy (Kawagoe et al., 1999).  
Golub et al. (1999) showed that expression of HOXA9 is the only single gene expression 
marker from over 6800 cDNAs after DNA micro-array analysis, as well as a diagnostic 
marker of AML in humans that is shown to be the most consistent. According to Armstrong 
et al. (2002), an important element of leukaemogenesis fuelled by MLL translocations is 
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aberrant expression of HOXA9. Molecular analysis studies of translocations t(7;11) and 
t(2;11) provide evidence that HOX genes HOXD13 and HOXA9 are targets of leukaemia-
associated genetic alterations. Particular homeobox gene families are known as 
leukaemogenic and mutations of homeobox genes are have been observed in leukaemia 
(Raimondi et al., 1999; Look et al., 1997). As well as the aberrant expression of wild-type 
HOX genes in AML (Beverloo et al., 2001; Iwasaki et al., 2005; Kroon et al., 2001; Von 
Bergh et al., 2006). 
 
1.4.3 Motor neuron and pancreas homeobox1 (HLXB9-MNX1) gene and reported 
mechanism of leukaemogenesis 
MNX1 (HLXB9) is a member of homeobox genes family. It is expressed in neuronal cells 
during differentiation (Liu and Joyner, 2001). In addition, HLXB9 is involved in pancreas 
differentiation (Harrison et al., 1999).  Dysregulation of HLXB9 causes Currarino Syndrome 
(Ross et al., 1998). HLXB9 gene is localized on chromosome 7 at band q36. An over-
expression of this gene has been observed in leukaemia cells that carry the translocations 
t(7;12)( Beverloo et al., 2001; Von Bergh et al., 2006) and t(6;7) (Nagel et al.,2005).  
The t(7;12) and HLXB9/ETV6 fusion transcript 
It has been reported that HLXB9 gene on 7q36 is a partner gene for ETV6 gene in the 
t(7;12)(q36;p13) (Beverloo et al., 2001). Beverloo and her group identified two paediatric 
patients with AML and an HLXB9/ETV6 fusion transcript. The chimeric fusion gene is 
created by the HLXB9 promoter and it is predicted to code for a protein that contains the N-
terminal 231 amino acids of HLXB9 and almost the complete ETV6 protein including the 
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pointed domain and the ets domain. The homeodomain of HLXB9 is not included in the 
fusion.  
The ETV6 gene on 12p13 is a member of the ETS family that encodes transcription factor. 
More than 40 chromosomal translocations are confirmed to be involved with the ETV6 gene 
in several types of leukaemia (Bohlander et al., 2005).  
Beverloo et al. (2001) found that in a study on paediatric patients, HLXB9/ETV6 fusion 
transcript was detected in around 20% of cases, and suggested that transformation for these 
fusions could have been due to HLXB9/ETV6 proteins interacting through the pointed domain 
with the wild-type ETV6, which would interfere with normal ETV6 function. 
 However, studies of various breakpoints in the HLXB9/7q36 region have shown that the 
t(7;12) rearrangement does not always result in the formation of a fusion transcript. However, 
the presence of an ectopic expression of the non rearranged HLXB9 gene is detected in all 
t(7;12) leukaemias. This would suggest that the mechanism of leukaemogenesis does not 
necessarily involve the generation of a chimeric protein in some t(7;12) cases (Von Bergh et 
al., 2006).  
 
The t(6;7) rearrangement and an ectopic expression of HLXB9 by juxtaposition of the 
MYB gene on the GDM-1 cell line  
The function of ectopically expressed HLXB9 in hematopoietic cells is unknown (Nagel et 
al., 2005). However, Nagel has confirmed successfully in his study an ectopic expression of 
HLXB9 due to juxtaposition of this gene with regions upstream of MYB in the GDM-1 cell 
line via the t(6;7) rearrangement. 
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Nagel’s is based on expression analysis using RT-PCR of genes flanking the breakpoint 
region C7ORF2, C7ORF3, HLXB9, and ubiquitin protein isopeptide ligase E3, at 7q36. All 
genes at 7q36 were expressed in all hematopoietic cell lines, whether neoplastic or normal 
except HLXB9 that was only expressed in the GDM-1. The HLXB9 gene expression was 
unnoticeable in 19 other AML cell lines, in 17 T-cell lines, and in 22 additional 
hematopoietic cell lines. 
Interestingly, 3 of 8 non- haematopoietic (prostate and cervix carcinoma) cell lines expressed 
HLXB9. This finding might support an oncogenic role for this gene. 
RT-PCR analysis using two different oligonucleotide primer pairs for HLXB9 (7q36) and for 
HBS1L (centromeric to the 6q23 breakpoint) revealed no fusion. These data pin down 
HLXB9, at 7q36, as the only possible particular target of the t(6;7) in GDM-1 cell line (Nagel 
et al., 2005).  
Recently, MYB was recognized as a second-hit target in AML (Castilla et al., 2004), 
supporting cooperative roles for HLXB9 and MYB in this situation.  
Apparently, the most likely neoplastic role for t(6;7) in GDM-1 is ectopic transcription of 
HLXB9 by juxtaposition with regulatory elements of an activated MYB allele, perhaps 
chromosomally mediated, though cytogenetic release of HLXB9 from upstream repressors 
cannot be excluded (Nagel et al., 2005). 
. 
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1.5 Aims  
 
The main aim of my project is to verify the involvement of homeobox genes in the biology of 
leukaemia. In particular, my interest focuses on the HLXB9 gene, located on chromosome 7 
and reported to be involved in some types of leukaemia. 
In order to achieve this goal, my objectives are: 
(i) Verify the involvement of chromosome 7 through the study of chromosomal 
abnormalities in leukaemia and lymphoma cell lines.  This will be achieved by G-
banding analysis and 24 colour karyotyping methods (Chapter 3) 
(ii) Verify the involvement of chromosome 7 in a series of patients with leukaemia 
using chromosome painting (Chapter 4) 
(iii) Verify the involvement of HLXB9 in a series of patients with leukaemia using 
single locus probes (Chapter 5). 
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CHAPTER 2 
 
 
 
 
 
 
 
 
 
 
 
  
MATERIALS AND METHODS 
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2. Materials and Methods 
 
 
2.1 Preparation of target genetic materials 
 
 
2.1.1 Origin of patients’ materials 
Patients’ materials of bone marrow were delivered in a form of archival methanol-acetic acid 
fixed chromosome suspensions stored at -20ºC. The G-banding analyses of the samples were 
carried out previously in the diagnostic lab that provided the samples. The patients’ samples 
were provided by Professor Jochen Harbott, Children’s University Hospital, Giessen, 
Germany.  
 
2.1.2 Cell lines 
In this study, three cell lines were used. Two cell lines were derived from myeloid leukaemia 
and one cell line was derived from lymphoma.  
 
 
2.1.2.1 Cell line GDM-1 
 
The GDM-1 is an acute myeloid leukaemia (AML) cell line was established from the 
peripheral blood of a 65-year-old female patient who had acute monoblastic leukaemia prior 
to her death (Ben-Bassat et al., 1982). This cell line was commercially obtained by the 
National Institute for Cancer Research, Genova, Italy. 
 
 
2.1.2.2 Cell line K562 
 
The K562 is a chronic myeloid leukaemia (CML) cell line that established from the pleural 
effusion of a patient with Philadelphia chromosome positive (Ph +) chronic granulocytic 
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leukaemia (Lozzio & Lozzio, 1975). The cell line was provided in a form of fixed cells 
suspension by a collaborator (University of Oxford). 
 
 
2.1.2.3 Cell line Pfeiffer (CRL-2632) 
 
The Pfeiffer (CRL-2632) cell line is a lymphoma cell line. It was derived from the 
lymphoblast cells of a patient in the leukemic phase of diffuse large cell lymphoma (DLCL) 
with cleaved and non-cleaved nuclei (Gabay et al., 1999). The cell line was purchased in a 
form of live cells culture (ATCC, UK). 
 
2.1.3 Cell culture 
The GDM-1 cell line was cultured in 80% RPMI 1640 medium (Gibco) supplemented with 
20% (v/v) foetal calf serum (FCS) (Gibco), 2% (v/v) penicillin and streptomycin antibiotics 
(Gibco) and 2mM L-glutamine (Gibco). All reagents used for the cell culture were warmed to 
37ºC in a water bath before being used. The cells were maintained at 37ºC in an incubator 
containing 5% CO2. The cells were then seeded in a T25 tissue culture 25 ml flask (Thermo 
scientific, UK). The medium was changed twice a week until the growth of cells was 
obtained, and then passages were started. The growth of the cells was checked every 2 days 
using a 10X lens of a phase contrast light microscope. The cells were treated with Colcemid 
(0.05mg/ml) for 1 hour before harvesting to arrest mitotic chromosomes. 
 
 
 
 
 
 
 
 
 
28 
 
2.1.4 Harvesting of cell cultures 
 
 
The cells were centrifuged at 1200 RPM (MSE, Centaur2E centrifuge, UK) for 5 minutes. 
The supernatant was discarded and the pellet was re-suspended in 10 ml of hypotonic solution 
(0.075M potassium chloride-KCL) at 37ºC. After incubation for 15 minutes, the cells were 
centrifuged again for 5 minutes at 1200 RPM. The supernatant was then discarded and the 
pellet was re-suspended in a 10 ml of fresh fixative solution containing three parts methanol 
and one part acetic acid. After incubation for 15 minutes at room temperature, the cells were 
centrifuged as described previously. Fixative solution washes were carried out twice. The 
fixed chromosomes and cells were re-suspended in a small amount of fresh fixative solution. 
The cells suspension was stored at -20ºC until required.  
 
2.1.5 Preparation of slides  
The fixed cell suspensions were centrifuged at 3000 RPM for 5 minutes and the supernatant 
was discarded. The cell pellets were re-suspended in a small amount of fresh methanol: acetic 
acid fixative solution usually 150µl to achieve an appropriate concentration. Eight µl of fixed 
cells suspension were dropped from a height (8cm) onto the middle of a dry clean slide 
(Superfrost, UK). The slides were air-dried and the quality of metaphases and chromosome 
spreads were checked by a contrast inverted microscope. The slides were aged by leaving 
them on the bench for 2 days at room temperature. The slides were ready for FISH 
investigation at this stage. 
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2.2 Staining and banding of chromosome slides 
 
 
2.2.1 G-banding 
 
In a coplin jar, slides were treated with Trypsin solution (3ml of 0.25% stock Trypsin with 47 
ml of 0.85% Sodium Chloride NaCl) for 20 seconds at room temperature (RT). Some 
leukaemia cell lines slides were treated longer with Trypsin up to 60 seconds as slides were 
aged over a week.  The slides were transferred to a coplin jar containing 0.9% Sodium 
Chloride Saline (9g of NaCl dissolved in a litre of pure water) for 20 seconds at RT. Next, 
slides were transferred to a coplin jar of Gurr buffer solution (6.8pH, 1 tablet of Gurr buffer 
dissolved in a litre of distilled water) for 20 seconds at RT. The staining solutions were 
prepared in a coplin jar by mixing 3 mls   of each Giemsa’s and Leishman’s stains. The coplin 
jar was topped up with 6.8PH Gurr Buffer. The slides were left to stain for 7 minutes at RT. 
Then, were washed with cold water and dried on a hot plate at 58ºC for 15 minutes. The slides 
were protected by 22X40 mm cover slips and sealed with Eukite glue. The quality of 
chromosomes staining was assessed by an inverted microscope.  
Over-trypsinized chromosomes were very pale with the loss of a few chromosomal segments. 
In contrast, under-trypsinized chromosomes were very dark without an appearance of the light 
bands within a chromosome. 
 The over-stained chromosomes were destained by treating slides with a fresh fixative 
solution (3Methanol:1 acetic acid) for a few seconds, then re-stained for a shorter period of 5 
minutes. 
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2.3 Preparation of DNA probe 
 
 
2.3.1 DNA isolation of P1 artificial chromosome (PAC) clones 
 
The P1 artificial chromosomes were preserved in bacterial single colonies in the P1 derived 
host. The PAC was provided in a form of glycerol stock at -70 by Dr. Tosi, Brunel University, 
UK. The bacterial cells containing the DNA sequences of the gene of interest were grown in 
2ml of LB broth medium (LB Broth Miller pre-Buffered capsule, Fisher Scientific, UK) 
supplemented with 12.5µg Kanamycin antibiotic in 15 ml-polypropylene tubes (Fisher 
Scientific , UK) overnight at 37ºC while shaking.  The cells were centrifuged at 3000 RPM 
for 5 minutes. The supernatant was discarded and the pellet was resuspended vigorously in 
300 µl of P1 solution (15mM Tris pH 8.0, 10Mm EDTA and 100 µg/ml RNase A). The 
suspension was transferred into a 2ml micro centrifuge tube containing 300 µl of P2 solution 
(0.2 M NaOH and 1% SDS). The suspension was mixed gently by inverting the tube several 
times and incubated for 5 minutes at room temperature. Then, 300 µl of P3 solution (3M 
Potassium acetate KOAc, pH 5.5) were added gradually. The tube was centrifuged at 10,000 
rpm for 10 minutes at 4°C.  . The supernatant was transferred into a new Eppendorf tube that 
already contained 800 µl of ice cold isopropanol. The tube was inverted several times and 
incubated over night at -20°C. After the incubation, the tube was centrifuged at 10,000 RPM 
for 15 minutes at 4°C. The supernatant was discarded and 500 µl of ice cold 70% ethanol was 
added and the tube was inverted several times to wash the pellet. The tube was centrifuged in 
a micro centrifuge at 10,000 RPM for 10 minutes at 4°C. The supernatant was discarded and 
the pellet left to dry for 2 hours at room temperature. The DNA pellet was re-suspended in 
20µl of water once it completely dried. The pellet was left for 2 hours at the bench with 
tapping the tube gently to dissolve. The pellet was stored at -20ºC. 
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2.3.2 Agarose gel electrophoresis 
 
The purified PAC DNA was run on mini gel electrophoresis (7x10cm) to validate the DNA 
size. The DNA sample was diluted with water to achieve a final volume of 5µl to be mixed 
with 1µl of DNA dye. The mixture was loaded in   1% agarose gel with DNA size marker III 
(PeQlab, Erlangen, Germany). The gel electrophoresis was run in TBE buffer (0.089 M Tris, 
0.089 boric acid and 2Mm EDTA, Ph8.0) at 80 volts for 1 hour. The Gels were stained with 
ethidium bromide (0.5µg/ml) and visualised by a UV transilluminator (Alpha Innotech 
Corporation, California, U.S.A). 
 
 
2.3.3 Measurement of DNA concentration 
 
The concentration of purified DNA was calculated by using a Nano Drop Spectrophotometer 
(Nano Drop 2000C, Thermo scientific, and UK). A sample of 2µl DNA was loaded into the 
machine. The machine had to be cleaned with 2µl of water twice before loading the DNA 
sample. The reading of DNA concentration was given in ng/µl. 
 
2.4 Labelling of DNA probes 
  
 
2.4.1 Nick translation 
 
Nick translation system was used to label DNA probes with biotin to be used in FISH 
investigation (BioNick™ DNA Labelling System, Invitrogen, UK). In a small Eppendorf 
tube, 1 µg of DNA probe (5µl of PAC1121A15) was mixed with 5µl of 10xdNTP mix (0.2 
mM each dCTP, dGTP, dTTP, and 0.1mM dATP and biotin-14-dATP) and 5µl of the 
enzymes mix (DNA polymerase I and DNase I). In order to obtain a final volume of 50 µl, 35 
µl of pure water were added. The mixture was mixed and incubated at 16ºC for 2 hours. The 
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reaction was stopped by placing the DNA probe on ice or using stop buffer (0.5 M EDTA, 
pH 8.0). 
 
 
2.4.2 Agarose gel electrophoresis 
 
Obtaining a labelled DNA fragment between 100-500 bp in size is essential for efficient 
FISH hybridisation. After successful nick translation reaction the labelled fragment should be 
around 300 bp in size. In order to confirm the size of DNA fragment, a labelled DNA probe 
was run in 2% agarose gel and DNA size marker XIII (PeQlab, Erlangen, Germany). The gels 
were run in TBE buffer at 80 Volts for 45 minutes. The gels were stained with Ethidium 
Bromide (0.5µg/ml) and visualised with a UV transilluminator (Alpha Innotech Corporation, 
California, U.S.A). 
 
 
2.4.3 Purification of labelled probes 
 
Unincorporated nucleotides of the labelled probe were removed using microSpin G-50 
Columns (Illustra MicroSpin G-50 Columns, GE health care life sciences, UK). The labelled 
probe obtained by nick transaction (approximately 50µl) was placed at the top of the column. 
The column was centrifuged at 6000 RPM for 3 minutes then discarded.  The purified DNA 
probe was collected and was mixed with 5µl of salmon sperm (11mg: 1g), 10µl of Sodium 
Acetate (NAAC) and 2.25 volumes of ice- cold 100% Ethanol. The labelled DNA probe was 
precipitated at -70ºC for an hour. The mixture was centrifuged at 13000 RPM for 30 minutes 
at 4ºC. The supernatant was discarded and the pellet was washed in ice-cold 70% Ethanol. 
The tube was centrifuged again at 13000 RPM for 15 minutes at 4ºC. The supernatant was 
discarded and the pellet left to dray at room temperature for 2 hours. The pellet was re-
suspended in 20µl of pure water for overnight at 4ºC. The purified labelled DNA probe was 
stored at -20ºC until needed. 
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2.5 Fluorescence in situ hybridization 
 
 
2.5.1 Denaturation of the target DNA 
 
The aged slides were washed in saline-sodium citrate (2XSSC, pH7.0) while shaking for five 
minutes (SSC buffer in 20Xconcentration, Sigma, UK). They were then dehydrated through 
an alcohol series (70%, 90% and 100% ethanol) followed by air-drying for five minutes. The 
slides were denatured in 70% formamide denaturing solution containing 2XSSC at 70
o
 C for 
5 minutes. Following the denaturation, the slides were instantly plunged into ice-cold 2XSSC 
for five minutes, then dehydrated again through an alcohol series (70%, 90% and 100% 
ethanol) and air-dried at room temperature. The denatured slides were ready to hybridize with 
the denatured probe at this stage. 
 
 
2.5.2 Competitive in situ suppression 
 
In order to block the repetitive sequences of the genomic DNA, PAC probes were annealed 
with a DNA competitor before the hybridization. In a small Eppendorf tube, 5µl of the 
purified labelled DNA probe was annealed with 5 µl of human COT 1 DNA (Roche 
Diagnostics GmbH, Germany).  The mixture was dried in a speed vacuum dessicator for 10 
minutes (Speed Vac® Plus SC110A, Sanvant Instruments Inc., Farmingdale, NY). Then, 
12µl of commercial hybridisation buffer was added. The hybridisation mixture was denatured 
at 80ºC for 10 minutes, placed on ice immediately and incubated at 37ºC for 15 minutes. 
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2.5.3 Hybridization 
 
The denatured DNA probe was added to denatured slides. The slides were covered with 22 
X22 mm glass coverslips (VWR international, UK). The slides were sealed with rubber 
solution and incubated in a humid chamber at or 37ºC for overnight. After the hybridisation 
the rubber solution was removed and the slides were washed in 2XSSC while shaking for 5 
minutes to remove the coverslip. The slides were washed in 0.4XSSC at 72ºC for 5 minutes 
then in fresh 2XSSC for 5 minutes to remove unbind probe. Finally, the slides were washed in 
phosphate-buffered saline (PBS) for five minutes while shaking (phosphate-buffered saline, 
Sigma, UK). For DNA visualization, 15µl of counterstained diamidino-2-phenylindole 
(DAPI) solution (Cambio, UK) was added for each slide. The slide was covered with a 22X40 
mm coverslip and sealed with nail polish.  
 
 
2.5.4 Detection of hybridized, labelled probes  
 
Biotin-labelled probes   
Biotinylated probes were detected with avidin conjugated CY3 dye. The slides were treated 
with 100 µl blocking solution of 4% bovine serum albumin (w/v) (BSA in 4XSSC, 
0.05%Tween20) (Sigma, UK) for 20 minutes at 37ºC to block non-specific protein binding 
sites. The antibodies used in the detection were diluted in BSA. 
On each slide, 75µl of Streptavidin - CY3 conjugated were added, covered with a piece of 
parafilm and incubated in a humid chamber for 20 minutes at 37ºC. After the incubation the 
slides were washed 3 times in 4XSSC, 0.05%Tween20 while shaking for 5 minutes each. The 
second layer was 75µl of biotin- anti avidin conjugated. The slides were covered with 
parafilm and incubated for 20 minutes at 37ºC. The slides were washed 3 times in 4XSSC, 
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0.05%Tween20 while shaking for 5 minutes each. In order to amplify the weak biotinlated 
probe hybridized signal, a third layer of 75µl Streptavidin - conjugated CY3 was added to the 
slides. The slides were covered with parafilm and incubated in a humid chamber for 20 
minutes at 37ºC. The slides were washed in 4XSSC containing 0.05%Tween20 for 5 minutes 
shaking. Finally, the slides were washed finally in phosphate-buffered saline (PBS) for 5 
minutes shaking.  The slides were mounted in anti fading medium supplemented with DAPI 
(Vectashield, Vector laboratories, UK). 
 
2.6 Commercial painting probes 
 
 
The hybridisation using the whole chromosome 7 painting probe directly labelled with 
fluorescein isothiocyanate (FITC) was carried out according to the manufacturer’s 
instructions. The human chromosome 7 paint probe was mixed with the hybridisation buffer 
(1 part probe: 4 parts hybridisation buffer) to make a final volume of 15µl for each slide. The 
hybridisation mixture was denatured at 65ºC for 10 minutes and incubated at 37
o
C for 10 
minutes to allow re-annealing of repetitive sequences. The denatured probe (15 µl for each 
slide) was applied to the denatured slide and covered with a 22X22 mm glass coverslip. The 
coverslip was sealed by rubber cement glue and left to hybridise in a moist chamber at 37
o
C 
overnight. After hybridisation, the glue was gently removed and the slide was washed in 
2XSSC for five minutes while shaking in order to remove the coverslip. The slide was then 
washed in pre-warmed 0.4XSSC for five minutes in a water bath at 72
o
C (diluted from 20X 
SSC buffer, Sigma, UK). The slide was washed in 2XSSC for five minutes at room 
temperature while shaking. It was then washed in phosphate-buffered saline (PBS) for five 
minutes while shaking (phosphate-buffered saline, Sigma, UK). For each slides 15µl of 
diamidino-2-phenylindole (DAPI) solution (Cambio, UK) was added. The slide was covered 
with a 22X40 mm coverslip and sealed with nail polish. 
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2.7 Multiplex FISH (M-FISH) 
 
The method here described has been used according to the instruction given by the 
manufacturer of M-FISH probe-set (Metasystem , Altlussheim, Germany).  
 
2.7.1 Aging of the slides 
The slides were incubated in 3:1 methanol: acetic acid for an hour and then, dehydrated in 
Ethanol series 70%, 90% and 100% for 2 minutes each. The slides were baked at 65° C for 20 
minutes, and then placed in acetone for 10 minutes, and then air-dried. 
 
2.7.2 Pre-treatment of slides with RNase 
The slides were treated with RNase (100µg/ml in 2XSSC) for 1 hour at 37° C. The slides 
were washed in 2XSSC then in phosphate buffered saline (PBS). 
 
2.7.3 Formaldehyde fixation 
The slides were washed in (PBS) containing Magnesium Chloride (50 mM of MgCl2) for 5 
minutes. Then, the slides were incubated in a solution of PBS containing 50mM (MgCl2) and 
1% paraformaldehyde for five minutes at room temperature. Finally the slides were washed in 
1X PBS for five minutes at room temperature.  
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2.7.4 Slide denaturation: 
The slides were washed in 0.1XSSC for 1 minute at room temperature, and then denatured 
with 70% formamide in 2XSSC at 70°C for 30 minutes. The slides were then allowed to cool 
on the bench for a proximately twenty minutes. Once slides cooled, they were sequentially 
washed with 0.1XSSC and 0.07 N NaOH at room temperature for 1 minute each. Followed by 
0.1XSSC and 2XSSC washes at 4°C for one 1 minute each. The slides were dehydrated in 
ethanol series at 30%, 50%, 70% and 100% for 1 minute each and then air-dried. 
 
2.7.5 Probe denaturation and hybridisation 
Ten microliters of 24XCyte commercial painting probe (Metasystem kit, Altlussheim, 
Germany) was placed into an Eppendorf tube and denatured at 75° C for 5 minutes. The probe 
is light sensitive, therefore it was kept in the dark (Eppendorf tube was covered with 
aluminium foil). The probe was then placed on ice for 10-20 seconds and then incubated at 
37° C for 30 minutes, and then briefly centrifuged and placed on the slide. A 22X22 mm 
coverslip was placed onto the probed area of denatured slide and sealed by rubber cement 
solution. The slides were incubated at 37° C in a humidified chamber for 3 days.  
 
2.7.6 Post-hybridisation washes 
After incubation, the rubber cement and coverslips were removed and the slides were washed 
in 1XSSC at 73ºC then in 4XSSC containing 0.05% tween 20 for 5 minutes respectively. 
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2.7.7 Detection 
One µl of detection reagent was added to 50 µl blocking reagent and mixed. The mixture was 
applied to the probe area of the slide and covered with parafilm, then incubated at 37 C° for 
15 minutes in a humidified box. The slides were washed twice in 4XSSC containing 0.05% 
tween 20 for 3 minutes each, then once in PBS while shaking at room temperature. The slides 
were air-dried. The DNA was counterstained with 20µl of DAPI. The slides were covered 
with 22X40 mm coverslip and sealed with nail varnish. The slide was stored at 4° C in the 
dark until required. 
 
2.8 Image analysis  
 
 
2.8.1 Microscopy 
 
 
2.8.1.1 G-banded chromosomes 
G-banded metaphases chromosomes were visualised and analysed using Zeiss Axioskop 
microscope (Zeiss, Oberkochen, Germany) connected to a digital camera used for capturing 
images at 100X objectives oil focus.  
 
2.8.1.2 Single and dual colour FISH 
For single and dual colour FISH, the slides were visualised and analysed using the Olympus 
BX41 fluorescence microscope and UPlanFLN 100X oil immersion lens. A minimum of 
twenty metaphases were analysed for cell line and minimum of five metaphases were 
analysed for patients. For some patients there were a limited number of metaphases due to the 
poor quality of the delivered materials.  
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2.8.1.3 M-FISH 
For M-FISH metaphase analysis an 8-positions filter equipped fluorescent microscope was 
used (AXioplan2 imaging, Carl Zeiss, Germany). The microscope contains individual filter 
sets for each component fluorochrome of the XCyte probe cocktail plus DAPI (FITC, DEAC, 
Spectrum orange, Texas Red and CY5).  
Digital FISH images were captured using a charged-coupled device (CCD) camera. 
Metaphases chromosomes were analysed and karyotyped by enhanced DAPI banding. Further 
paint analysis was achieved by assessing paint coverage of each individual fluorochrome 
along the entire length of each chromosome. A metaphase was considered normal if all 46 
chromosomes were observed to be normal with that procedure, and consequently confirmed 
by the Isis Software of M-FISH analysis. At least 25 metaphases were analysed for each cell 
lines. 
 
2.8.2 Specific software for analysis 
 
 
2.8.2.1 G-banding analysis software 
 
 
Specific G-Banding software was used to analysis the metaphases chromosomes spreads. 
These were CytoVision (Applied Imaging Corporation, UK) and Genikon software (Nikon, 
UK). 
2.8.2.2 FISH analysis software 
Single and dual colour FISH Metaphase images were captured using a greyscale digital 
camera (Digital Scientific, UK) and Smart Capture 3 software (Digital Scientific, UK). 
M-FISH metaphases chromosomes were analysed and karyotyped using ISIS software 
(Metasystem Isis, Altlussheim, Germany). 
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CHAPTER 3 
 
 
 
CHARACTERIZATION OF CHROMOSOMAL ABERRATIONS IN 
MYELOID LEUKAEMIA AND LYMPHOMA DERIVED CELL LINES 
USING CONVENTIONAL CYTOGENETIC TECHNIQUE (GBANDING) 
AND MULTIPLEX FISH (M-FISH) 
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3.1. Introduction 
3.1.1 Complex chromosomal aberrations (CCAs) 
Chromosomal abnormalities are a hallmark for disease progression and classification in 
cancer, including leukaemia. Recurrent chromosomal abnormalities have been identified in all 
leukaemia subtypes as sole aberration present or as part of a complex karyotype.  
Complex chromosomal aberrations (CCAs) which involve more than two chromosomes 
and/or more than three breakpoints have been observed in Leukaemia. CCAs have been 
reported in 20% of de novo acute myeloid leukaemia (AMLs), 24% of secondary AMLs and 
up to 50% of therapy-related AML and MDS cases (Mauritzson et al., 2000; Rossi et al., 
2000). 
CCAs are associated with rather poor prognosis and respond poorly to anti-leukaemic 
treatment and it was suggested that some of these rearrangements contribute to drug resistance 
and disease progression (Lindvall et al., 2004; Schoch et al., 2001).  
Cryptic chromosomal translocations (that impossible to detect by G-banding method) are 
common findings in leukaemia (Cherif et al., 1993; Pan et al., 2012; Tosi et al., 1996, 1997   
and in this study chapter 4). 
 
3.1.2 The GDM-1 cell line 
The GDM-1 is an acute myeloid leukaemia (AML) cell line was established from the 
peripheral blood of a 65-year-old female patient who had acute monoblastic leukaemia 
(AML-M4) (Ben-Bassat et al., 1982).  
The attempts of establishing the GDM-1 cell line from the patient blood peripheral were 
carried out several times before the growth of the leukemic cells was obtained.  The patient 
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sample was cultured in glass flasks that contain RPMI 1640 medium supplemented with 30 % 
foetal calf serum and antibiotics to achieve a final cell concentration of 2-4 × 106 cells/ml. 
The cells were maintained at 37°C with 5% CO2 in air and 80-95% relative humidity (RH) 
with changing the medium twice a week (Ben-Bassat et al., 1982). 
The characterization of GDM-1 cell line abnormalities was carried out using conventional 
cytogenetic technique G-banding. It enabled the identification of various chromosomal 
abnormalities, such as trisomy 8, deletion of chromosome 6, del(6q), an additional genetic 
material on chromosome 7, add (+7q), and a deleted chromosome 12(12p).  The G-banding 
karyotype of 47, XX, +8, del(6)(q), add(7)(q), del(12)(p) was observed in 85% of cells 
analysed (Ben-Bassat et al., 1982).  
A more detailed G-banded karyotype of the GDM-1 cell line, that included refined 
breakpoints of several abnormalities,  was reported as 
48,XX,der(2)t(2;11)(q36;q13),t(6;7)(q23;q36),+8,del(12)(p11.2p12.2),+13,del(16)(q23) 
(Nagel et al., 2005). In should be noted that in this latter report a t(2;11) and a del(16) has 
been observed. 
The GDM-1 cell line present the translocation t(6;7)(q23;q36) with an over expression of the 
HLXB9 gene and distal break point at 7q36. These features make the cell line a good model to 
study the t(6;7) and the mechanism of leukaemogenesis that related to the activation of 
HLXB9 in AML –M4 subtype in vitro.  
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3.1.3 Conventional cytogenetic technique (G-banding) 
 G-banding analysis is a first line investigation enabling a scanning of the whole DNA 
genome at the chromosomal level. It is a widely used technique for the routine staining of 
mammalian chromosomes. The aim of the technique is to produce a banding pattern within 
chromosomes that facilitates karyotypic analysis. Chromosomal bands are generated by 
staining with Giemsa’s and Leishman’s stains after pre-treating chromosomes with Trypsin. 
This causes chromosomes to stain as a series of dark G bands and pale inter-bands. Each 
homologous chromosome pair has a unique pattern of G-bands enabling chromosomes 
analysis under the microscope by eye or by using special software such as CytoVision or 
Genikon (Sander Operation Procedure, Paediatric Malignancy Unit, Great Ormond Street 
Hospital, London, UK). However, complex chromosomal aberrations (CCAa) may be 
difficult to interpret by banding methods and cryptic chromosomal translocations are not 
detected by G-banding; for example, cryptic translocations are not detected or have been 
misdiagnosed as deletions in conventional cytogenetic G-banding analysis (Cherif et al., 
1993; Pan et al., 2012; Tosi et al., 1996 and 1997).  
 The limitation of G-banding approach can be overcome by combining the information 
obtained by G-banding analysis with further molecular cytogenetic methods, such as 
multiplex FISH, that obtains a 24-colour karyotype.  
 
3.1.4 Multiplex cytogenetic technique (M-FISH) 
Multiplex fluorescence in situ hybridization (M-FISH) technique allows the visualization of 
all human chromosomes in 24 colours by using a cocktail probe of whole chromosomes paints 
in a single hybridization (MetaSystems, Altlussheim, Germany).  
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The recognition of 24 different chromosome painting probe is obtained with five varicolored 
fluorochromes (FITC, DEAC, Spectrum Orange, Texas Red and Cy3). Individual paint is 
labelled with one of these five fluorochromes or with a unique combination of them. The 24 
colour karyotype results in a mixture of these five different fluorochromes. Suitable filter sets 
are used to guarantee the separation of different excitation and emission spectra. This 
technique allows the production of a special colour for each chromosome which facilitates the 
analysis of numerical and structural abnormalities especially cryptic and complex 
chromosomal abnormalities (MetaSystem lab manual, Altlussheim, Germany). 
The M-FISH analysis is facilitated by the aid of specially designed software for metasystem 
images analysis (ISIS) and an axioplan epifluorescence microscope (ZEISS, Germany). 
3.2 Aim of the study 
The aim of this chapter was to characterize the chromosomal aberrations in myeloid 
leukaemia and lymphoma derived cell lines that present an over-expression of HLXB9 gene. 
In order to achieve this goal, information obtained by conventional cytogenetic technique (G-
banding) and molecular cytogenetic technique (M-FISH) were combined.  
 
3.3 Materials and methods 
3.3.1 Cell line 
The human acute myeloid derived cell line GDM-1 and chronic myeloid derived cell line 
K562 were used in this study. In addition, one lymphoma cell line CRL2632 has been 
investigated (See chapter 2 for a detailed description of the cell lines). 
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The GDM-1 cell line was obtained from the National Institute for Cancer Research, Genova, 
Italy. The culturing of GDM-1 cells, harvesting and preparations of slides was carried out as 
described in the materials and methods chapter (Chapter 2). 
The K562 cell line was provided via collaboration with Oxford University, UK while the 
Pfeiffer cell line -CRL2632 was purchased from the American Type Culture Collection-
ATTC.   
All three cell lines were delivered in the form of live cell cultures. However, the harvesting of 
cells and chromosomes for GDM-1 was carried out by myself, whereas the same procedure 
for K562 and Pfeiffer cell lines was performed by others in the group and I handled these two 
cell lines in the form of fixed chromosomes and cell suspensions.  
 
3.3.2 Probe 
 
The Meta System 24XCyte probe containing 24 different chromosomes paints was used in 
this study (Metasystem kit, Illustras, Germany). The probe was kindly provided by Dr. Rhona 
Anderson, Brunel University, UK. 
3.3.3 G-banding analysis  
The aged slides were treated with trypsin and Giemsa dye according to G-banding procedure 
as described earlier (Chapter 2). (Stander Operation Procedure, Paediatric Malignancy Unit, 
Great Ormond Street Hospital, London, UK). The karyotype obtained after G-banding 
analysis was described according to conventional cytogenetic nomenclature (ISCN, 2009).   
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3.3.4 Multiplex fluorescence in situ hybridization 
The hybridization was carried out according to Metasystem protocols. The whole procedure is 
described in details in chapter 2. 
 
3.3.5 Image capture and analysis for G-banding 
An Olympus microscope that connected to a digital camera was used for capturing images at 
100 objectives oil focus. Specific G-Banding software was used for analysis such as 
CytoVision and Genikon. Image capture and analysis was performed by myself during my 
training period at the laboratory of Paediatric Malignancy Unit, Great Ormond Street 
Hospital, London, under the supervision of Dr Steve Chatter.  
 
3.3.6 Image capture and analysis for M-FISH 
Twenty metaphases were analysed for each cell line. The chromosomes were observed   using 
a fluorescence microscope (ZEIZZ, AXioplan2 imaging) and MetaSystem camera. Images 
analysis and karyotype of metaphase chromosomes were performed using Metasystem (ISIS) 
software.  
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3.4 Result 
3.4.1 G-banding and M-FISH analysis 
 3.4.1.1 Cell line K562 
In the present work complex chromosomal abnormalities of 2 leukaemia cell lines (GDM-1 
and K562) and one lymphoma cell line (Peiffeir-CRL2632) were analysed using both classic 
cytogenetic technique (G-banding) and molecular cytogenetic technique (M-FISH).  
The G-banding analysis of the CML leukaemia cell line K562 revealed numerical and 
structural chromosomal abnormalities (Figure 3.1.A). The numerical aberrations consisted of 
14 trisomies (+1),(+2),(+4),(+5),(+6),(+8),(+10)(+11),(+12),(+15),(+16),(+17),(+19),(+21). 
Moreover, 4 copies of chromosome 7 were observed. The M-FISH analysis on K562 cell line 
has confirmed numerical abnormalities findings and more trisomies were detectable such as 
(+9), (+20), and 4 copies of chromosome 15. The G-banding analysis revealed additional 
materials on several chromosomes add (11p) and add (21p), as well 4 markers chromosomes.  
These 4 marker chromosomes were identified by M-FISH karyotype analysis.  
M-FISH analysis revealed several cryptic translocations that were not detected by G-banding 
analysis in the cell line such as t(1;21),t(5;6),t(6;18),t(3;10),t(9;17),t(11;13)and t(12;21). 
Moreover, add(11) and add (21) that were detected by G-banding analysis were identified as 
t(11;13) and t(1;21) resulting in der(11) and der(21) by M-FISH analysis (Figure 3.1, 1.B and 
2.B).  
Importantly, the ring Philadelphia chromosome resulting from (9;22) on the cell line was 
misdiagnosed by  G-banding analysis and detected by M-FISH analysis. Furthermore t(3;10) 
was detected in70% of the cells analyzed as 30% of the leukemic blast revealed the lack of 
this abnormality (Figure 3.1, B.2). 
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3.4.1.2 Cell line GDM-1 
G-banding analysis on the acute myeloid leukaemia derived cell line GDM-1 revealed trisomy 
8 and 13. Moreover structural abnormalities such as add(2q), del(6q) and add(7q) were also 
detected (Figure3.2, A). 
The del (6q) and add(7q) were refined using M-FISH analysis as a reciprocal translocation  
t(6;7) resulting in and der(7). The add(2q) was refined by M-FISH as t(2;11) resulting in 
der(2) . Furthermore, a del(16) was identified by M-FISH analysis (Figure3.2.B).  
 
3.4.1.3 Cell line Pfeiffer-CRL2632  
The lymphoma derived cell line (Pfeiffer-CRL2632) abnormalities were investigated using G-
banding and single and dual colour FISH. G-banding analysis revealed trisomy 5, 
isochromosome(8), add(11p), del(12p) and add(17q). Moreover 5 marker chromosomes were 
detected by G-banding analysis (Figure3.3). 
In order to identify these five markers chromosomes on the Pfeiffer cell line further FISH 
images were analysed. The images were kindly provided by Dr. Tosi for analysis (Figure 3.4 
A, B, C, D).FISH analysis confirmed G- banding findings of Trisomy 5 and isochromosome 
8. FISH using a whole chromosome paint for chromosome 5 (WCP5), was confirmed trisomy 
5 (Figure 3.4, A). Moreover, FISH using whole chromosome paint for chromosome 8 
(WCP8) and locus specific probe for C-MYC gene at 8q24 confirmed iso-chromosome 8, as 
we can see that the q arm is duplicated (Figure 3.4, B). FISH using WCP6 and WCP13 have 
confirmed derivative chromosome der(6),  del(6) and der(13) (Figure 3.4, C) that was 
detected by G-banding analysis as markers. However, FISH using WCP12 and WCP17 has 
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revealed a der(12) and a der(17) resulting from t(12;17). This cryptic translocation was 
detected by G-banding previously as deletion of (12p) and add(17q). 
 
3.4.2 Revised karyotypes after FISH 
3.4.2.1 The cell line K562 
The G-banding analysis of K562 revealed a very complex karyotype with 4 marker 
chromosomes. The karyotype obtained through G-banding analysis was 
64,XX,+1,del(1)(p?36),+2,+4,+5,del(5)(q?)+6,+7,+8,-9,+10,+11,add(11)(p12) ,+12,+15,+16, 
+17,+19,-20,+21,add(21) (q21).  
The karyotype obtained after  M-FISH was 68XX,+1,del(1)(p?36), +2,+4,+5,der(5)t(5;6), 
der(6)t(6;18),+6,+7,+7,+8,+9,del(9),der(10)t(3:,10),der(11)t(11;13),+11,+12,der(12)t(12;21) 
+15,+15,+16,+17,der(17)t(9;17),der(18)t(6;18),+19,+20,der(21) t(1;21), del(22),+22. This 
karyotype was detected in 70% of the cells analysed while 30% of the cells revealed a 
karyotype of 64 chromosomes.  
3.4.2.2 The GDM-1 cell line 
The G-banding analysis revealed a karyotype of 48,XX,add(2)(q34?),del(6)(q23), 
add(7)(q36),+8,+13. The revised the karyotype after M-FISH was revised to:  
48,XX,der(2)t(2;11)(q34;q?p),del(6),der(7),t(6;7)(q23;q36),+8,del(16)(q?). 
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3.4.2.3 The Pfeiffer cell line (CRL2632) 
The G-banding analysis indicated 5 marker chromosomes and revealed a karyotype of 
49,XY,+5,del(6),add(6),iso(8)(q11.1?p11.1),add(11)(p15),del(12)(p13),add(13)(q?),del(14)(q
?), +16,add(17)(q25). The 5 markers were identified by FISH analysis and the karyotype was 
modified to 
49,XY,+5,del(6),der(6)t(6;13),iso(8)(q11.1),der(12)t(12;17),der(13)t(6;13)+16,der(17)t(12;1)
. 
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A 
Figure 3.1 :( A) An example of G-banding karyotype of k562 cell line metaphase indicating 
numerical and structural abnormalities and karyotype of 64,XX,+1,del(1)(p?36), +2,+4, +5 
,del(5)(q?)+6,+7,+8,-9,+10,+11,add(11)(p12) ,+12,+15,+16, +17,+19,-20,+21,add(21) (q21).  
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Figure 3.1: (B.1) An example of K562 M-FISH karyotypes (found in 70% of the leukaemia blasts) revealed very 
complex karyotype and cryptic translocations that were not detected by G-banding only. M-FISH karyotype of 
68XX,+1,del(1)(p?36),+2,+4,+5,der(5)t(5;6),der(6)t(6;18),+6,+7,+7,+8,+9,del(9),der(10)t(3:,10),der(11)t(11;13),
+11,+12,der(12)t(12;21)+15,+15,+16,+17,der(17)t (9;17),der(18)t(6;18),+19,+20,der(21) t(1;21), 
+21,del(22),+22. 
 
B.1 
53 
 
 
Figure3.1:(B.2) An example of M-FISH karyotype that has been found in 30% of K562 cells of 64XX 
,+1,+2,+4,+5,der(5)t(5;6),+6,+7,+7,+8,del(9),+9,der(11)t(11;13),+11,+12,der(12)t(12;21)+15,+,+15,+16,+17,
der(17) t(9;17)del(18),+18  +19,+20, der(21)t(1;21)+21,del(22). 
 
B.2 
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A 
Figure3.2: (A)  An example of G-banded analysis of the GDM-1 cell line metaphases indicated 
abnormal karyotype metaphase revealed a karyotype of 48,XX,add(2)(q34?),del(6)(q23), 
add(7)(q36),+8,+13. 
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Figure3.2: (B) An example of M-FISH analysis on GDM-1 chromosomes detected numerical and 
structural abnormalities and a karyotype of 48XX,der(2)t(2;11),t(6;7), der(7),+8,del(12p),del(16q). 
. 
B 
B 
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Figure 3.3: An example of G-Banding analysis on CRL2632-Pfeiffer cell line revealed chromosomal 
abnormalities and abnormal karyotype with five markers as the arrows indicates. The Karyotype of Pfeiffer 
cell line is 49,XY,+5,del(6),add(6),iso(8)(q11.1?p11.1),add(11)(p15),del(12)(p13),add(13)(q?),del(14)(q?), 
+16,add(17)(q25). 
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D 
C 
Figure 3.4: Metaphase FISH images of Pfeiffer cell line. (A) FISH using WCP5 in red confirmed 
trisomy 5. (B) WCP8  in green and specific locus probe for C-YMC gene in red  confirmed 
iso(8)(q11.1). (C) Dual colour FISH using WCP6 in red and WCP13 in green confirmed 
der(6),der(13) and del(6). (D) Dual colour FISH using WCP12 in red and WCP 17 in green 
confirmed a reciprocal translocation t(12;17).  
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3.5 Discussion 
Chromosomal translocations are among the most common genetic abnormalities associated 
with lymphomas and leukaemia (Rabbitts, 1994). Changes in chromosome 7 have been 
identified in leukaemia and lymphomas in the form of loss of chromosome 7 material as well 
as translocations of chromosome 7. 
In this study conventional cytogenetic G-banding technique and molecular cytogenetic 
technique multiplex FISH (M-FISH), as well as single and dual colour FISH were applied to 
investigate very complex chromosomal abnormalities in leukaemia and lymphoma cell lines. 
All three cell lines have shown an over expression of HLXB9 gene (data not shown).  The 
human acute myeloid leukaemia (AML) cell line GDM-1 and chronic myeloid leukaemia 
(CML) cell line K562 were analysed, as well as a lymphoma cell line (CRL2632) also known 
as Pfeiffer). The use of this dual approach has helped in refining the chromosomal aberrations 
in these cell lines and enabled us to obtain a more accurate karyotype.  
The conventional cytogenetic technique G-banding was a useful screening tool to study the 
whole chromosomes abnormalities and identified the breakpoints within translocations. 
However, M-FISH technique was a powerful method to indicate cryptic translocations that 
were misdiagnosed as deletions by only G-banding analysis in the cell lines (K562 and GDM-
1) that have been analysed in this study. Therefore, M-FISH analysis was enabled a more 
accurate karyotype by identifying the origin of translocated genetic material between 
chromosomes. 
The power of M-FISH analysis in unravelling very complex rearrangements and cryptic 
translocations has been reported previously by other groups (Hilgenfeld et al., 2001; Mathew 
et al., 2001; Naumann et al., 2001; Nordgren et al., 2001). 
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However, M-FISH is a low-resolution molecular technique enabling a broad screening of the 
gross chromosomal aberrations. The combination of M-FISH analysis and classic banding 
technique enables the establishment of an accurate karyotype. This is due to the M-FISH 
enabling the identification of the origin of chromosomes involved in a specific rearrangement, 
whereas the conventional cytogenetic approach enables the assigning of specific breakpoints 
due to the availability of a precise banding pattern.    
M-FISH on K562 cell line was previously reported. This cell line is well known and widely 
studied as a model of CML and because it harbours a Philadelphia ring chromosome r(22) 
resulting from (9;22). 
Naumann et al., 2001 established a complete karyotype of the K562 cell line using G-banding, 
M-FISH, FISH using whole chromosome painting and locus specific probes and comparative 
genomic hybridization (CGH). This study showed that structural abnormalities of 
chromosome 7 were present beside the numerical abnormalities reported before. Two 
abnormal copies of chromosome 9 have been indicated while our data confirm 3 copies of 
chromosome 9, of which two copies are abnormal. Interestingly 4 copies of chromosomes 10 
and 12 (of which 2 copies of each were abnormal) and 11 (of which one copy was abnormal) 
were confirmed. The following trisomies of chromosomes 1, 2, 4, 6, 15, 16, 17, 19, 21 and 22 
were confirmed and in agreement with the M-FISH analysis here reported. Importantly four 
copies of chromosome 5 have been confirmed and this matches our finding. Moreover, in 
Naumann study the following derivative chromosomes der(5), (10),der(11),der(12),der(17) 
and der(21) have been confirmed which support our data. 
In the study presented here, the GDM-1 cell line was analysed using M-FISH for the first 
time. The M-FISH revealed a very similar karyotype to G-banding analysis that was reported 
by Nagel (Nagel et al., 2005). This finding showed that G-banding is a valuable tool to detect 
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the chromosomal abnormalities despite the difficulty of identifying the added or deleted 
genetic materials origin and the special training it requires. 
 
3.5.1 Conclusions 
These studies enabled more analysis of gross chromosomal abnormalities in leukaemia and 
lymphoma cell lines that are associated with over-expression of HLXB9. The GDM-1 cell line 
was shown previously (Nagel et al., 2005 and in this study) to carry t(6;7)(q23;q36) with 
breakpoint at 7q36, which makes it a good candidate to study HLXB9 gene furthers as it 
localises at the same breakpoint. M-FISH was a good method to indicate gross chromosomal 
abnormalities. Unfortunately, the investigation of the HLXB9 gene could not be done by M-
FISH due to the lower resolution of the technique. 
The characterisation of chromosomal abnormalities in cell lines is a starting point on which to 
base more refined studies at the gene level. The work here described here has allowed the 
discrimination of different types of abnormalities in cell lines characterized by over-
expression of the HLXB9 gene. As the HLXB9 gene is localized on chromosome 7, it was 
expected to find abnormalities involving this chromosome. In fact, this was the case in the 
myeloid leukaemia cell lines K562 and GDM-1, where both numerical (K562) and structural 
(K562 and GDM-1) abnormalities were found. The Pfeiffer cell line has not shown any 
abnormality of chromosome 7 with the methodologies applied here. Therefore, the reason for 
HLXB9 over expression needs to be investigated further.  
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3.5.2 Future work  
Future work will involve investigations into the mechanisms of activation for HLXB9 gene 
expression. To date, little is known about the factors that induce over-expression of HLXB9 
and there is scope for more research in this area. One of the cell lines studied here, GDM-1, 
has been already used in this sense and the Myb gene has been proposed to promote HLXB9 
over-expression being juxtaposed to HLXB9 by virtue of the t(6;7) rearrangement(Nagel et al., 
2005). The precise molecular mechanisms by which this occurs have yet to be elucidated.  
Similarly, more work is needed to clarify the mechanisms of HLXB9 over-expression in the 
other two cell lines described here. In K562, HLXB9 over-expression might be due to the 
presence of additional copies of chromosome 7. The situation might be more complex in the 
case of the Pfeiffer cell line, where no abnormalities of chromosome 7 have been reported. 
Studies at the molecular level will shed some light on these mechanisms. However, these are 
out of the scope of this project. In order to confirm the chromosomal abnormalities that were 
indicated by M-FISH, further FISH using specific probe of the HLXB9 will be carried out. 
Such experiments will be shown in the GDM-1 cell line and in a series of patients in chapter 5 
of this thesis. 
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CHAPTER 4 
 
 
 
 
 
 
 
CHARACTERIZATION OF CHROMOSOME 7 ABNORMALITIES IN 
ACUTE MYELOID LEUKAEMIA (AML) DERIVED CELL LINE 
(GDM-1) AND AML PATIENTS USING WHOLE CHROMOSOME 
PAINTING 
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4.1 Introduction 
4.1.1 Aberrations of chromosome 7 in myeloid leukaemia  
Characterization of chromosomal abnormalities is essential to better understand and diagnose 
haematological malignancy. Two different categories of clonal chromosome abnormality are 
identified in acute myeloid leukaemia (AML): unbalanced rearrangements that are associated 
with gain or loss of chromosome materials and a balanced rearrangement without gain or loss 
of chromosome genetic materials (Pedersen-Bjergaard and Rowley, 1994).  
Chromosomal deletions are characterized by the absence of chromosome segments. Deletions 
are classified as terminal if the missing genetic materials are localized by the chromosome 
edge (Figure 4.1 (A)), and interstitial if the deleted genetic materials are within the 
chromosome arms (Figure 4.1(B)) (Genetic home reference hand book, 2012). 
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Figure 4.1: (A) An example of ideogram illustrates terminal deletion that occurs on the 
chromosome end and affected telomere region. (B) An example of ideogram illustrates interstitial 
deletion that localizes within the chromosome long or short arms and occurs between 2 breakpoints 
at the same arm of a chromosome. 
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Chromosomal translocations are one of the most common abnormalities associated with 
lymphomas and leukaemia (Rabbitts, 1994). Translocations are characterized by the exchange 
of DNA segments between two different chromosomes. This is balanced when there is no loss 
or gain of chromosome material (Figure 4.2) and unbalanced when there is a gain or loss of 
chromosomes material (Figure 4.3) (Genetic home reference hand book, 2012). 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
            Chromosome A 
Chromosome B 
der(A) 
der(B) 
Segments exchanged 
p arm 
q arm 
Figure 4.2: An example of ideogram illustrates the balanced translocation with exchange between 
two segments on two different chromosomes (A) and (B). The derivative chromosomes der(A) and 
der(B ) show  the translocated  genetic material on each. 
Figure 4.3: An example of ideogram illustrates unbalanced translocation that shows a normal 
chromosome (A). In addition the derivative of chromosome (A) der (A) with the presence of 
additional material derived from another chromosome and the deletion of the chromosome long 
arm genetic material. 
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The identification of genetic alterations in AML patients has a significant importance in 
classification, prognosis and response to the treatment.  
Numerous chromosomal translocations have been associated with a specific subtype of AML. 
Various chromosomal regions that frequently show gains or losses have been identified in 
leukaemia. In addition, the involvement of some genes in leukaemogenesis has been 
established as shown in (Table 4.1) (Zutven, 2005). 
      Clonal abnormality                Phenotype           Genes involved 
11q23 rearrangements  AML and other leukaemia          MLL-partner gene 
t(15;17)(q22;q12)                  AML           PML-RARA 
t(8;21)(q22;q22)                  AML          AML1-ETO 
-5/del(5q)  AML and other leukaemia  
-7/del(7q)  AML and other leukaemia  
11p15 rearrangements  AML and other leukaemia           NUP89 
t(7;12)(q36;p13) AML and very rare in other 
leukaemia 
         ETV6/HLXB9 
 
 
 
 
 
 
Table 4.1: The most frequent chromosomal abnormalities associated with AML and other 
types of leukaemia with some genes that have been involved. This table modified from 
(Zutven, 2005). 
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Several chromosomal abnormalities are associated with good or poor prognosis; for example,  
t(15;17)(q22;q12), t(8;21)(q22;q22) and t(16;16)(p13q22) are connected with favourable 
outcomes and a high rate of patient survival (Von Neuhoff, et al., 2010). However, the 
deletion of 7q is associated with poor prognosis. 
Loss of chromosome 7 material, whether of the whole chromosome or part of it, is a common 
finding in myeloid disorders (Beau et al., 1996). 
Myeloid leukaemia disorders involving the long arm of chromosome 7, del(7q), are clinically 
associated with a short survival time, poor prognosis and poor response to chemotherapy 
(Bernstein et al., 1984). 
Several deleted segments on 7q have been identified in myeloid leukaemia. The deletion of 
7q22 has been reported previously (Curtiss et al., 2005; Le Beau et al., 1996; Fischer et al., 
1997) and 7q31–q32 and 7q33 (Tosi et al., 1999). In addition, the deletion of 7q32-33 
segment is also a known feature (Beau et al., 1996) and the deletion of 7q35-q36 region 
(Döhner et al., 1998) 
However, the interstitial and terminal deletions of 7q  that was described earlier in this 
introduction (Figure 4.1 (A) and (B)) have been identified previously by FISH using WCP7 
and specific probes for chromosome 7 centromere and telomere regions (Tosi et al., 1996).  
Tosi’s study was able to identify five patients with interstitial deletions of 7q and three 
patients with terminal deletions of 7q. 
4.1.2 Chromosomal Translocations involving 7q36 
The chromosomal translocations associated with loss of the whole or main material of 7q 
were detected by FISH in leukaemia patients (Bernstein et al., 1984). 
The acute myeloid leukaemia cell line, GDM-1, is characterized by the presence of 
t(6;7)(q23;q36) with a break point in the 7q36 region. The translocation resulted in the 
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MYB/HLXB9 rearrangement and over expression of the HLXB9 gene on the GDM-1 cell line. 
The translocation has been confirmed by conventional cytogenetic technique G-banding (Ben-
Bassat et al., 1982) and detailed fluorescence in situ hybridization studies (Nagel et al., 2005). 
The 7q36 region is observed to be rearranged in the GDM-1 cell line and particular AML 
patients with t(7;12)( q36;p13) and indicated a breakpoint within the 7q36 region where the 
HLXB9 gene is localized. An over expression of HLXB9 has been associated with these 
chromosomal rearrangements in the GDM-1 cell line and such patients. 
The presence of t(7;12) (q36;p13) is associated with infant leukaemia. It has been reported in 
one third of AML patients under the age of two years with poor outcomes (Tosi et al., 2003; 
Von Bergh et al., 2006). The t(7;12) has resulted in the rearrangement of the ETV6/HLXB9 
genes. However, the ETV6- HLXB9 fusion transcript has been found in approximately 50 per 
cent of t(7;12) patients  with  over-expression of HLXB9 (Tosi et al., 2003; Von Bergh et al., 
2006). 
4.1.3 Fluorescence in situ hybridization using the whole chromosome painting 
(WCP) approach in Leukaemia studies 
 Fluorescence in situ hybridization (FISH), using whole chromosome painting (WCP), is an 
accurate tool that allows the visualization of each individual chromosome’s origin by staining 
the length of chromosome in metaphase spreads and interphase cells (Chevret et al., 2000).  
Two decades ago, chromosome painting technique was established by two independent 
research groups at (Pinkel et al., 1988; Cremer et al., 1988). The groups had taken advantage 
of the accessibility of cloned DNA libraries that were derived from flow-sorted human 
chromosomes (Gray et al., 1975). 
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The principle of this method is based on the hybridization of previously labelled a nucleic 
acid probe to target DNA sequences of fixed cells or tissues. Following hybridization, the 
hybridized signals can be visualized using special filters and a fluorescence microscope.  
FISH, using whole chromosome painting, is a powerful technique to reveal cryptic 
unbalanced translocations that are not detected or have been misdiagnosed as deletions in 
conventional cytogenetic G-banding analysis (Bennour et al., 2012; Cherif et al., 1993; Pan et 
al., 2012; Tosi et al., 1996 and 1997).  
However, the limitations of chromosome painting probes are apparent. The detection of 
interchromosomal structural abnormalities, such as translocations, is greatly higher than 
intrachromosomal aberrations such as deletions or inversions. The latter abnormalities are 
difficult to detect because the genetic material involved in the rearrangement would be 
stained with the same fluorochrome that stains the rest of the chromosome. The combination 
of conventional cytogenetic techniques such as G-banding and FISH analysis help to fill up 
this methodological gap (Lurie et al., 1980). 
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4.2 Aims of the study 
The aim of this work was to characterise the chromosomal rearrangements involving 
chromosome 7 in an AML cell line and patients in order to discriminate between deletions 
and translocations using the whole chromosome 7 painting technique.  
 In order to achieve this, FISH with the WCP7 will be used on the AML cell line (GDM-1) 
and on a series of AML patients. The chromosome 7 abnormalities were defined by G-
banding analysis previously in the GDM-1 cell line (Nagel et al., 2005) and in AML patients 
by the diagnostic lab (Children’s University Hospital, Giessen, Germany).  
4.3 Materials and methods 
4.3.1 Cell line and patients 
The human AML derived cell line, GDM-1, and seven AML patients that were characterized 
by the presence of chromosome 7 abnormalities were analysed to investigate the 7q 
rearrangement in this study. The patients’ materials were provided kindly by Professor Jochen 
Harbott at the Children’s Hospital, Giessen, Germany. The clinical and cytogenetic details of 
these patients are provided in (Table 4.2).  
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Pt     Sex/Age        Hematologic           Reported karyotype              Revised karyotype 
                                    disease                  (by G-banding)                    ( by FISH) 
 
1      M /5Years            AML-M4                  46,XY,del(7)(q33~34)           46,XY,add(7)(p11) 
2      F /11Years           AML-Mixed             46,XX,del(7)(q22)                                 _ 
3      F /3Years              AML                        45,XX,add(7)(q3?4),-9                          _ 
4      M /80Years           AML                        41~43,XY,del(7)(q?)              43,XY,add(7)(p11) 
5      F /15Years            AML-M4                 46,XX,del(7)(q22)                                _ 
6      M /13Years           AML-M4                 46,XY,del(7)(q22~q31)                        _ 
7      F /15Years            AML-M4                 46,XX,del(7)(?q22q31)           46,XX,add(7)(q?) 
 
Table 4.2: Clinical and Cytogenetic data of patients with Chromosome 7 rearrangement in 
this study. (-) means the karyotype was not revised by FISH and remained the same as 
reported by G-banding analysis. 
 
4.3.2 Cell culture 
The GDM-1 cell line was cultured as described in part 2.1.3 of chapter 2. 
4.3.3 Harvesting of cells 
The GDM-1 cell line was harvested as described earlier in part 2.1.4 of chapter 2. 
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4.3.4 Preparation of slides 
The GDM-1 cell line and AML patients’ chromosome suspension were spread as described in 
part 2.1.5 of chapter 2. 
4.3.5 Probe 
A whole chromosome 7 painting probe (WCP7) that was directly labelled with FITC and 
commercially obtained (Cambio, Cambridge, UK) was used to detect chromosome 7 
abnormalities in this study.  
4.3.6 Fluorescence in situ hybridization 
The aged slides were washed in saline-sodium citrate (2XSSC pH=7.0) while shaking for five 
minutes (SSC buffer in 20Xconcentration, Sigma, UK). They were then dehydrated through 
an alcohol series (70%, 90% and 100% ethanol) followed by air-drying for five minutes. The 
slides were denatured in 70% formamide denaturing solution containing 2XSSC at 70
o
 C for 
five minutes. Following the denaturation, the slides were instantly plunged into ice-cold 
2XSSC for five minutes, then dehydrated again through an alcohol series (70%, 90% and 
100% ethanol) and air dried at room temperature. The slides were ready to hybridize with the 
probe. The human chromosome 7 paint probe was mixed with the hybridisation buffer (1 part 
probe: 4 parts hybridisation buffer). The probe was denatured at 65ºC for 10 minutes and 
incubated at 37
o
C for 10 minutes to allow re-annealing of repetitive sequences. The 15µl of 
denatured probe was applied to the denatured slide and covered with a 22X22 mm coverslip. 
The coverslip was sealed by rubber cement glue and left to hybridise in a moist chamber at 
37
o
C overnight. At post hybridisation, the glue was gently removed and the slide was washed 
in 2XSSC for five minutes while shaking in order to remove the coverslip. The slide was then 
washed in pre-warmed 0.4XSSC for five minutes in a water bath at 72
o
C (diluted from 20X 
SSC buffer, Sigma, UK). The slide was washed in 2XSSC for five minutes at room 
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temperature while shaking. It was then washed in phosphate-buffered saline (PBS) for five 
minutes while shaking (phosphate-buffered saline, Sigma, UK). For DNA detection, 15µl of 
diamidino-2-phenylindole (DAPI) solution (Cambio, UK) was added for each slide. The slide 
was covered with a 22X40 mm coverslip and sealed with nail polish. 
4.3.7 Image capture and microscope analysis 
The slides were visualised and analysed using the Olympus BX41 fluorescence microscope 
and UPlanFLN 100Xoil immersion lens. Metaphase images were captured using a greyscale 
digital camera (Digital Scientific, UK) and Smart Capture 3 software (Digital Scientific, UK). 
A minimum of twenty metaphases were analysed for GDM-1 cell line and minimum of five 
metaphases were analysed for patients. In some patients there were a limited number of 
metaphases due to the poor quality of the material.  
4.4 Results   
 The GDM-1 cell line and seven AML patients with 7q abnormalities were analysed in this 
study. FISH using the whole chromosome 7 paint (WCP7) was used to validate the karyotype 
obtained previously by G-banding. Chromosome 7 painting analysis confirmed chromosome 
7 rearrangements in two main categories: deletions and translocations. 
The G-banding findings of del 7q were confirmed in 3 patients (Patient nos. 2, 5 and 6) 
However, the G-banding abnormal karyotype was modified by FISH in 3 patients (Patient 
nos. 1, 4 and 7) as shown in (Table 4.2). 
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4.4.1 Deletions of 7q 
Based on the combination of both G-banding analysis and FISH using WCP7 analysis we 
were able to confirm 3 deletions of 7q in patients (Patient nos. 2, 5 and 6). In these patients, 
the normal chromosome 7 and del(7) were completely painted. FISH analysis images were 
taken in two patients, with del(7)(q22 ) (Patient nos. 2 and 5) (As shown in Figure 4.4 and 
Figure 4.5) and one patient (Patient no. 6) with del(7)(7q22~q31) (Figure 4.6).  
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Figure 4.4: (A) An Example of FISH performed on metaphase chromosome obtained from 
patient No. 2 using WCP7 FITC (visible in green).  The white arrow indicates del(7q) that 
shows the deletion of 7q22 materials. (B) With the same image as (A) showing DAPI only. 
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Figure 4.5: (A) An Example of FISH performed on metaphase chromosome obtained from 
patient No. 5 using WCP7 FITC (visible in green). The white arrow indicates del(7) that 
shows a shorter chromosome 7 with deletion. (B) The same image as (A) with DAPI only. 
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Figure 4.6: (A) An example of FISH performed on metaphase chromosomes obtained from 
patient No.6 using WCP7 FITC (visible in green). The white arrow indicates del(7) that 
shows deleted bands of chromosomes 7(q22~q31). (B) The same as image (A) with DAPI 
only. 
 
A 
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4.4.2 Balanced translocation in the GDM-1 cell line 
FISH using WCP7 analysis on the GDM-1 cell line confirmed a chromosomal translocation 
involving chromosome 7. FISH images analysis showed normal chromosome 7 that was fully 
painted and derivative 7, der(7), which was partially painted, confirming an additional DNA 
material was translocated from another chromosome (Figure 4.7). Unfortunately, the 
translocated part of chromosome 7 was not detected by FISH using WCP7, as the region is 
quite small and not detectable   by that approach. The balanced translocation t(6;7)(q23;q36) 
of the GDM- cell line was studied in details (Nagel et al., 2005). 
 
 
4.4.3 Unbalanced translocations involving chromosome 7 in AML patients 
FISH using WCP7 successfully detected three unbalanced translocations in AML patients that 
were reported previously as deletions of 7q in G-banding karyotype (patient nos. 4, 7 and 1). 
In these patients, normal chromosome 7 was fully painted and the abnormal chromosome 7, 
der(7), was partially painted with the presence of additional genetic  materials. These 
unbalanced translocations are shown in (Figures 4.8, 4.9 and 4.10). 
Furthermore, a translocation on one patient (patient No. 3) was detected by G-banding 
analysis previously and was also confirmed by FISH analysis (Figure 4.11). 
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Figure 4.7: An example of FISH experiment using WCP7 (FITC) in green on 
GDM-1 cell line chromosomes. The arrow shows additional material on 
derivative 7 delivered from other chromosomes that confirms a translocation on 
the GDM-1 cell line. 
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Figure 4.8: (A) An example of FISH performed on metaphase chromosome obtained from 
patient No. 4 using WCP7 FITC (visible in green). The white arrow indicates der (7) that 
shows additional materials on 7p11. (B) With the same showing DAPI only. 
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Figure 4.9: (A) An Example of FISH performed on metaphase chromosomes obtained from 
patient No.7 using WCP7 FITC (visible in green). The white arrow indicates der(7) that 
shows additional materials on derivative chromosome 7. (B) The same image as (A) with 
DAPI only. 
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Figure 4.10: (A) An example of FISH performed on metaphase chromosomes obtained from 
patient No1 using WCP7 FITC (visible in green). The white arrow indicates der(7)(q) 
chromosome with additional genetic materials. (B) The same image as (A) with DAPI only. 
A 
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Figure 4.11: (A) An example of FISH performed on metaphase chromosome obtained from 
patient No. 3 using WCP7 FITC (visible in green). The white arrow indicates der(7) that 
shows the presence of additional material derived from another chromosome. (B) The same 
image as (A) showing DAPI only. 
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4.4.3 The revised patients’ karyotype by FISH 
 
FISH was used with WCP7 to modify the G-banding investigation analysis in 3 patients as 
follows: 
   Patient 1 
 
Patient 1 was a five-year-old boy. The diagnostic lab G-banding karyotype was 
46,XY,del(7)(q33~34). This karyotype was revised after FISH analysis, as FISH using WCP7 
defined a chromosomal translocation with a deletion of the entire chromosome 7 long arm 
del(7q) as shown in (Figure 4.10).  
Patient 4 
 
Patient 4 was an 80-year-old with G-banding karyotype of 41~43,XY,del(7)(q?). This 
patient’s G-banding karyotype revealed a deletion of chromosome 7 long arm del(7)(q) with 
no breakpoint specification. FISH using WCP7 confirmed unbalanced translocation and the 
karyotype was revised to 43,XY,add(7)(p11) for this patient. We were able to identify the 
breakpoint of this patient at p11 as it is possibly within the chromosome 7 centromere  (Figure 
4.8). 
Patient 7 
 
Patient 7 was a 15-year-old with G-banding karyotype of  46,XX,del(7)(?q22q31). G-banding 
analysis revealed 7q deletion for this patient. FISH was used with WCP7 to revise the 
chromosome 7 q deletion to an unbalanced translocation. It was not possible to identify the 
breakpoint for this patient by using FISH with whole chromosome painting as WCP7 paint is 
not an accurate tool to investigate the breakpoints (Figure 4.9). However, from the FISH 
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image the breakpoint could be estimated around 7q22. Therefore, the revised abnormality in 
this case could be add(7) (q22). 
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4.5 Discussion 
 
In this study, the whole chromosome painting technique was used to classify the chromosome 
7 rearrangements as deletions or translocations in the AML patients which had been analysed 
previously by conventional cytogenetic technique G-banding. 
FISH using WCP7 confirmed (del)(7q) that was detected previously by G-banding in 3 
patients. Two segments were approximately identified by G-banding and FISH analysis 
del(7) (q22) and del(7)( 22~ 3 ). This finding is in agreement with Fischer’s study of 
fluorescence in situ hybridization (FISH) in leukaemia patients (Fischer et al., 1997). The 
analysis on 7q deletions has defined 7q22 and 7q22~31 previously as common deleted 
regions (Fischer et al., 1997).  
In Fischer’s study, deletion of 7 22 was defined in 2 cases of chronic myeloid leukaemia and 
deletion of 7q22~q31 was reported in the AML cases. However, in the present study we 
reported two cases of 7q22 deletions and one case of 7q22~q31 deletion in AML patients. 
Le Beau’s and colleagues have used a series of YAC probes in FISH specifically to study the 
7q22 breakpoint on myeloid patients, this study has identified 7q22 region as a common 
deleted region in twenty-seven patients (Le Beau’s et al.,  996).  Additionally, that study has 
identified breakpoints on 7q22 on other nine AML patients with balanced translocations.  
  All these results, and in the agreement with some other studies (Curtiss et al., 2005; Kratz et 
al., 2001) which have suggested that some 7q regions such as 7q22 or 7q31 might contain a 
tumour suppressor gene (TSG), which plays an important role in preventing normal cells 
developing into cancer cells. However, a recent study ,Wong’s study, using a chromosome 
engineering to model a segment 7q22 deletion in myeloid leukaemia in a vivo (mouse) does 
not support that theory (Wong el al., 2010). 
87 
 
On some occasions, the whole chromosome painting proved to be a more accurate technique 
than G-banding to detect cryptic unbalanced translocations. FISH analysis using WCP7 re-
defined some rearrangements from deletions as previously reported by G-banding to be 
unbalanced translocations with the omission of chromosome 7 long arm materials (Patient 
nos.1 and 4). The importance of the whole chromosome painting in detecting cryptic 
translocation which is not detected by G-banding was reported previously (Pan et al., 2012; 
Tosi et al., 1996 and 1997). 
FISH using WCP7 on the GDM-1 cell line has confirmed chromosomal translocation. The 
study of t(6;7)(q23;q36) has been reported (Nagel et al., 2005) using G-banding analysis and 
FISH using specific probes for the 6q23 and 7q36 regions. 
 The whole chromosome painting is a powerful application to investigate cryptic 
translocations; in the meantime it showed a limitation in the identification of the exact break 
point by only FISH analysis. However, the combination of G-banding and FISH analysis 
enabled us to give an approximate estimate of the breakpoints in some cases in this study. 
Further FISH investigations using specific probes along the different regions of chromosome 
7 are required to confirm the breakpoints.  
 
4.5.1 Conclusions 
In this study, WCP7 analysis was used to identify chromosome 7 rearrangements in AML cell 
line and patients. Three patients with 7q deletions have been reported. Moreover, four patients 
were associated with unbalanced translocation. Three of these translocations were cryptic and 
not visible in G-banding analysis.  
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4.5.2 Future work 
The GDM-1 cell line that present add(7q) along with the AML patients with a deletion of 7q 
will be investigated in a further detail by using a FISH study, which applies a specific probe 
for the HLXB9 gene at 7q36 as will be described in the next chapter (Chapter5). This will 
determine the exact breakpoint in the cell line and whether the 7q deletions on patients are 
intersetial. 
The four AML patients with the unbalanced translocations will not be investigated by FISH 
using specific probe for HLXB9 at 7q36 region, as the breakpoints in these patients are 
proximal to 7q36. This means that the 7q36 band has been deleted and HLXB9 gene is lost. 
 The study outlined in this chapter served the purpose of selecting those patients with 7q 
deletions and discarded those patients with unbalanced translocations that involved the loss of 
the telomeric region of chromosome 7, and  because of the loss of a large segment in 7q, we 
can assume that in these cases the HLXB9 gene is also lost.   
Further studies (as described in chapter 5 in this thesis) will focus on a selected series of 
patients with del(7q), hoping that these are interstitial, to check whether HLXB9 gene is 
present. This will be done by FISH using a specific locus probe for HLXB9 gene. 
 The GDM-1 cell line carries the t(6;7)(q23;q36) with over-expression of the HLXB9 gene 
indicated distal breakpoint to HLXB9 on 7q36 region, which makes it a model cell line to 
study t(6;7) in AML (Nagel et al., 2005).  The breakpoint is within band 7q36 and close to the 
HLXB9 gene and might the breakpoint resulting in an over-expression of the HLXB9 gene. 
 However, ETV6 is a transcription factor that has been identified as a partner gene of HLXB9 
in t(7;12) (q36;p13)( (Beverloo et al., 2001). Interestingly the involvement of MYB on 6q23 
with HLXB9 via t(6;7) has been established by Nagel (2005). MYB is a proto oncogene that is 
involved in leukaemogenesis and has been reported to be over-expressed in acute leukaemias 
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(Sinclair et al., 2005). However, the involvement of MYB with HLXB9 has been so far 
reported only in the GDM-1 cell line (Nagel et al., 2005). Further studies to support this 
finding will be plausible.  
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CHAPTER 5 
  
 
 
 
 
 
       FISH STUDIES OF THE HLXB9 GENE IN MYELOID DISORDERS 
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5.1 Introduction 
5.1.1 The t (7;12) rearrangements and the association with childhood leukaemia 
and HLXB9 over expression 
The t(7;12) (q36;p13) is a common chromosomal translocation associated with infant 
leukaemia and clinically poor outcome (Tosi et al., 2003; Von Bergh et al., 2006). It is found 
approximately in one third of infant AML leukaemia. In contrast, it is rare in infant ALL and 
older AML patients. To date, it has never been reported in adult AML cases (Tosi et al., 2003; 
Von Bergh et al., 2006). According to von Bergh and her group’s study in 2006 that covered 
59 AML patients, 18 of them were infants. The study indicated that six cases carried the 
t(7;12)(q36; p12) and five of them were infants aged between 0 and 12 months, and one was 
18 months old. This finding suggested that the t(7;12) is found in about 30% of infant AML. 
In contrast, only one case carried t(7;12) (q36;p13) in all 290 ALL patients.  
The t(7;12) results in the rearrangement of the ETV6/TEL gene at (12p13) (Tosi et al., 2003; 
Von Bergh et al., 2006). Alteration of the ETV6 gene occurs at its 5’ end and involving fusion 
with chromosome 7 at various breakpoints such as 7q22 and 7q36 (Tosi et al., 2003; Von 
Bergh et al., 2006). Dr. Tosi and her group’s study, which is based on fluorescence in situ 
hybridization (FISH) and Southern Blotting analysis, reported  an interesting  case of t(7;12) 
(q22;p13) that also included a breakpoint at 7q36 genomic region (Tosi et al., 2003).  
Furthermore, the breakpoints in the 7q36 region in the t(7;12) cases are heterogeneous 
(Simmons et al., 2002; Tosi et al., 2003). Studies of the breakpoints in the t(7;12) support an 
involvement of HLXB9 as partner of ETV6 gene (Beverloo et al., 2001). However, the ETV6- 
HLXB9 fusion transcript has been found in approximately 50% of t(7;12) cases. The over-
expression of HLXB9 has been reported in all t(7;12) patients reported to date (Ballabio et al., 
2009; Von Bergh et al., 2006).    
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5.1.2 The over-expression of HLXB9 gene in acute myeloid leukaemia derived cell 
line GDM-1 via t(6;7) rearrangement 
Activation of expression of HLXB9 has been reported in translocations other then the t(7;12). 
This is the case of the myeloid leukaemia derived cell line GDM-1 where it has been shown 
that the balanced chromosomal translocation t(6;7)(q23;q36) is the cause of over-expression 
of HLXB9 due to the juxtaposition of the MYB gene on 6q23  (Nagel et al., 2005 ).  
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5.2 Aim of the study 
 
The main aim of this study was to localise the HLXB9 gene in cases with reported 
abnormalities of chromosome 7 in order to define whether the gene was deleted, disrupted or 
located on a derivative chromosome.  
The following are the specific objective for this study:  
(i) To analyse the status of HLXB9 by FISH in a series of patients with reported del(7), in 
order to assess whether this gene is lost (as a consequence of the deletion) or 
retained (because it is outside of the deleted region). 
(ii) To determine the 7q36 breakpoint on the GDM-1 cell line in relation to HLXB9. 
 
5.3 Materials and methods 
 
The material presented in this chapter was provided to me by my supervisor in the form of 
FISH images. Experiments were performed by others. 
 
5.3.1 Cell line and patients sample  
The human acute myeloid leukaemia derived cell lines (GDM-1) and 4 acute myeloid 
leukaemia (AML) patients were analysed in this study. The cell line and patients shared the 
presence of chromosome 7 abnormalities, add(7q) in GDM-1 cell line and del(7q) in AML 
patients. The cell line carries t(6;7)(q23;q36) and breakpoint distal to HLXB9 gene on 7q36 
t(6;7)(q23:q36) (Nagel et al., 2005). The patients carried deletions with breakpoint within 
chromosome 7 away of 7q36 (telomeric region of chromosome 7) as shown in table 5.1. 
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The genetic materials Ch.7 abnormalities karyotype 
GDM-1 cell line          add(7)(q36) 47,XX,+8,del(6)(q),add(7)(q),del(12)(p) 
Patient 94-20          del(7)(q22) 46,XY,del(7)(q22) 
 
Patient 94-2086           del(7)(q?) 46,del(7q) 
 
Patient C            del(7)(q22) 45,XX,del(7)(q22),-21 
Patient K            del(7)(q22) 46,XY,del(7)(q22) 
 
 
Table 5.1: Chromosome 7 abnormalities and the karyotype of GDM-1 cell line as reported by 
Ben-Bassat et al., 1982, and AML patients as reported by the diagnostic lab. 
 
5.3.2 Probes 
In order to investigate the HLXB9 gene at 7q36 in the GDM-1 cell line and AML patients 2 
probes were used: 
(i) A whole chromosome 7 paint commercially available and directly labelled with FITC 
visible in green (Cambio, Cambridge, UK). This probe (WCP7) was used to 
identify the origin of chromosome 7 genetic materials. 
(ii) In house prepared locus specific probe PAC H_DJ1121A15 for the HLXB9 gene at 
7q36. The PAC probe was labelled with biotin and detected with streptavidin 
conjugated with CY3 visible in red as described in details in chapter 2 of this 
thesis.  
95 
 
In order to study the breakpoints of GDM-1 cell line further, 2 probes were hybridised 
simultaneously: 
(i) PAC clone of H_DJ1121A15 for HLXB9 gene at 7q36. The probe was labelled with 
digoxigenin and detected with FITC visible in green. 
(ii) PAC clone of 48H15 for distal region of HLXB9 gene. The probe was labelled with 
biotin and detected with CY3-avidin visible in red. 
All PAC clones used in this study were kindly provided by Professor Steve Scherer, 
Department of Genetics, Hospital for Sick Children, Toronto, Canada. 
The labelling system method of the probe was described in details in chapter 2 in this 
thesis. 
 
5.3.3 Fluorescence in situ hybridization 
FISH protocol for the whole chromosome painting was carried out as recommended by 
the manufacturer and is described in materials and methods of chapter 4. Moreover, the 
FISH protocol for using PACs was described in details on materials and methods chapter 
(Chapter 2) of this thesis.  
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5.4 Results 
5.4.1 Dual colour FISH investigation using WCP7 and specific PAC for the 
HLXB9 gene 
Dual colour FISH analysis of the AML patients and the GDM-1 cell line revealed no 
abnormalities of the HLXB9 gene at 7q36.  
FISH using WCP7 and unique sequences probe for the HLXB9 gene on the 4 AML patients   
indicated normal chromosome 7 and del(7q). The normal chromosomes 7 and del(7q) on the 
all AML patients were fully painted in green, although del(7q) appeared shorter which 
confirmed the deletions. Two red FISH signals for the HLXB9 gene were detected in all of the 
4 patients on both normal chromosome 7 and del(7q) (Figures 5.2, 5.3, 5.4 and 5.5). 
In the GDM-1 cell line, FISH using the whole chromosome painting WCP7 and PAC 
H_DJ1121A15 for HLXB9 showed normal chromosome 7 fully painted in green  and 
derivative chromosome 7, der(7),  partially painted in green with the presence of the HLXB9 
gene  red signals in both (one on each chromatid within a chromosome) as shown in (Figure 
5.1).  
 
5.4.2 Dual colour FISH investigation using specific probes for the HLXB9 gene 
(PAC 1121A15) and distal region (PAC48H15) 
This investigation was performed on the GDM-1 cell line only in order to achieve a detailed 
localization of the breakpoint in 7q36 in the cell line. The metaphase chromosomes and 
interphase nuclei were analysed. The FISH images analysis of GDM-1 metaphases showed 
green signals of the HLXB9 gene on both normal chromosome 7 and derivative der(7). 
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However, the red signals specific for the probe distal to HLXB9, were only observed on the 
normal chromosome 7.  The simultaneous visualization of green and red FISH signals showed 
that the normal chromosome 7 harboured both, whereas the der(7) harboured only green 
signals. No red signals for the PAC 48H15 were seen on the der(7). Interestingly, a red FISH 
signal for PAC 48H15 was localised on another chromosome (Figure 5.6). This chromosome 
is most likely to be chromosome 6 according to published data (Nagel et al., 2005).  The 
analysis of the GDM-1 cell line interphase nuclei showed a fused green-red signal, one single 
green signal and one single red signal. The analysis on both metaphase and interphase cells 
showed that the chromosome 7 breakpoint in the der(7)t(6;7) is in the region between PAC 
1121A15 and PAC48H15 (Figure5.7).  
 
 
  
 
Figure 5.1: An example of dual colour FISH experiment performed on metaphase obtained from  GDM-1 
cell line using WCP7 (visible in green) and PAC H_DJ1121A15 for HLXB9 (visible in red).The white 
arrow indicates the derivative chromosome 7; der (7) that clearly shows an additional material of DNA 
that delivered from other chromosome. The red signals for the HLXB9 gene show no abnormalities within 
7q36 region. 
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Figure 5.2: An example of a dual FISH experiment performed on metaphase obtained from patient 
94-20  using WCP7 (visible in green) and PAC H_DJ1121A15 for HLXB9 (visible in red).The white 
arrow indicates the del (7) that shows a deletion  of 7q material and present of  HLXB9 gene red 
signals on chromosome 7 and del(7q). 
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Figure 5.3: An example of a dual FISH experiment performed on metaphase obtained from 
patient 94-2086 using WCP7 (visible in green) and PAC H_DJ1121A15 for HLXB9 (visible 
in red). The white arrow indicates the del(7) that shows a deletion of 7q material, but does not 
involve the HLXB9 gene at 7q36 region. The red signal for HLXB9 gene is present 
.  
Figure 5.4 : An example of a dual FISH experiment  performed on metaphase obtained from 
patient C using WCP7 (visible in green) and PAC H_DJ1121A15 for HLXB9 (visible in 
red).The white arrow indicates the del(7) that shows a deletion of 7q material. Red signals for 
HLXB9 are present on both normal chromosome 7 and del(7q). 
 
 
100 
 
 
Figure 5.5: An examples of a dual colour FISH experiment performed on metaphase obtained 
from patient K using WCP7 (visible in green) and PAC H_DJ1121A15 for HLXB9 (visible in 
red). The white arrow indicates the del(7) that shows a deletion of 7q material Red signals for 
HLXB9 are present on both normal chromosome 7 and del(7q). 
 
101 
 
 
 
 
 
 
      RP5-1121A15 
        48H15 
                                          Ch7                                                        der7                                              der6 
 
                                                                                        
Figure 5.6: (A) An example of a dual colour FISH experiment performed on metaphase 
obtained from GDM-1cell line using PAC RP5-1121A15 for HLXB9 at 7q36 (visible in 
green) and PAC 48H15 for a region distal to HLXB9 (visible in red). The arrowhead shows 
normal chromosome 7 that has a fused signal in red and green. A green signal for HLXB9 
A 
7q36 
p 
q 
48H15 
 
7q36 
 
RP5-1121A15 
B 
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gene is visible on the der(7) and a split red signal for PAC 48H15 is visible on der(6).  The 
white arrows indicate the derivative chromosome 6 and derivative chromosome 7, der(6) and 
der(7) respectively, that shows just one signal on each chromosome in red or green which 
suggests the telomeric region on ch.7 is translocated on the der(6). No evidence for the 
HLXB9 gene split signal was detected by FISH. (B) An ideogram illustrates the chromosomal 
translocation t (6:7) in GDM-1 cell line and the breakpoint is just between these 2 probes. 
 
 
ch7 
ch7 
der7 
der6 
der
7 
der6
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Figure 5.7: (A) An example of interphase FISH experiment on GDM-1 cell line nucleus that 
shows one fused signal (red and green) for normal chromosome 7 and two individual signals 
(one in red and one in green), which confirm a chromosomal translocations and the breakpoint 
is just between these two probes. (B) An Ideogram illustrates the chromosomal translocation. 
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5.5 Discussion 
Several studies have reported an involvement of HLXB9 in some leukaemia cases (Beverloo 
et al., 2001; Tosi et al., 2003 and Von Bergh et al., 2006).   In infant AML patients, the 
HLXB9 gene has been identified as a partner gene for the ETV6 gene in t(7;12) (Beverloo et 
al., 2001; Tosi et al., 2003). The translocation results in a fusion transcript of HLXB9-ETV6 in 
50% of t(7;12) patients and over-expression of the HLXB9 in the all of the t(7;12) patients 
reported to date (Tosi et al., 2003; Von Bergh et al., 2006).    
In the present study, the FISH localization of the HLXB9 gene has been investigated in AML 
cell line (GDM-1) and 4 AML patients. FISH investigation using a specific PAC clone (H_J 
1121A15) containing HLXB9 on AML cell line and patients indicated no involvement of the 
HLXB9 gene in any breakages or rearrangements. Furthermore, the breakpoint was proximal 
of the HLXB9 gene in all four AML patients that have been analysed in this study. In contrast, 
the breakpoint was confirmed to be distal to HLXB9 in the AML cell line (GDM-1).  
Previous studies of the t(7;12) cases have shown that the 7q36  breakpoint is usually proximal 
to HLXB9. This implies that, in these cases, the HLXB9 gene is translocated; hence, localized 
on the der(12) (Tosi et al., 2000 and 2003; Von Bergh et al., 2006).  
Tosi and collaborators (Tosi et al., 2000 and 2003) have investigated 7q36 breakpoint in 
details in 6 leukaemia patients with t(7;12) and rearrangement of the ETV6 gene using a series 
of PAC clones and cosmids to cover 7q22 to 7q36 region (from centromere to telomere) by 
FISH. The breakpoint was identified at 7q36 by G-banding analysis previously in the all 
patients. FISH using clone PAC H_DJ1121A15 containing HLXB9 showed a split signal in 
normal chromosome (7), der (7) and der (12) in 3 patients, which confirmed the breakpoint 
was within the same PAC clone at 7q36. Further FISH investigation was carried out using 2 
cosmids derived from this PAC on these patients.  The cosmids signals were detected in der 
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(12) in 2 patients, which confirmed the breakpoints at 7q36 was proximal to the the cosmids 
probes. On the other patients, the cosmids signal was not detected, which suggested the 
breakpoint was distal of the cosmids probe in these patients. This data support the 
heterogeneity of the breakpoints in patients. 
Tosi’s and her group’s study (Tosi et al., 2003) that was on fluorescence in situ hybridization 
(FISH) and Southern Blotting analysis reported an interesting case of t(7;12) (q22;p13) that 
also included a breakpoint  at 7q36 genomic region. This case showed there is no involvement 
of ETV6 gene rearrangement in t(7;12). However, this finding suggests that there is another 
mechanism of t(7;12), which does not include a significant role for the ETV6 gene. HLXB9 
expression was not investigated in this case. However, if HLXB9 is proved to be over-
expressed in this case, one could speculate that the breakpoint close to the HLXB9 gene region 
could be the triggering factor for causing leukaemogenesises. 
In some t(7;12) patients, over-expression of HLXB9 has been reported to associate with 
nuclear changed position. The HLXB9 gene is normally located toward the nuclear periphery. 
Interestingly, it has been reported to be towards a more nuclear interior position in t(7;12) 
(Ballabio et al., 2009). It seems gene position affecting mechanism could be an another 
possible mechanism that results in over-expression of the HLXB9 gene in some AML positive 
t(7;12)patients. 
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5.5.1 Conclusions 
The HLXB9 gene has been investigated in this study in AML cell line and 4 patients. The 
HLXB9 gene was not lost or disrupted either in the AML cell line or in the patients that have 
been analysed in this study. However, from the FISH patterns it was possible to deduce that 
the breakpoint in relation to HLXB9 was different in the cell line compared to all del(7q) 
patients. 
 
5.5.2 Future work 
To date, there is no supporting data of HLXB9 gene breakage or rearrangement in leukaemia 
(particularly AML patients). However, the over-expression of the HLXB9 has been 
established in AML patients by several groups (Beverloo et al., 2001; Tosi et al., 2003; Von 
Bergh et al., 2006). 
The level of HLXB9 expression must be investigated in more leukaemia patients, as some 
data showed support of the expression of HLXB9 in very limited numbers of ALL patients 
and AML patients negative t(7;12) (Ballabio et al., 2009; Von  Bergh et al., 2006). The study 
of the HLXB9 gene in more leukaemia patients might enable the identification of a sub-group 
of leukaemia patients that share the expression of HLXB9.  
Following from the data analysed in this chapter, it would be interesting to see whether the 
expression of HLXB9 is observed in patients with interstitial del(7q) that do not show loss of 
HLXB9. This would prove that the disruption of 7q36 in a region proximal to HLXB9 is 
sufficient to promote its expression.  
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                                 GENERAL DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
108 
 
6. General discussion 
 
6.1 Understanding chromosomal abnormalities using conventional and molecular 
cytogenetics 
In present study, both conventional cytogenetic (through G-banding analysis) and molecular 
cytogenetic (through chromosome painting, 24 colour painting and single locus probe FISH) 
were performed on leukaemia and lymphoma cell lines, as well as on patients materials. The 
scope of this study was to understand, at the chromosomal level, a possible cause of activation 
of the homeobox gene HLXB9 resulting in the expression. All three cell lines analysed in this 
study are characterized by the expression of HLXB9. This was proven by reverse transcription 
(RT)-PCR experiments carried out in our lab (personal communication with Dr. Sabrina 
Tosi). It is known that HLXB9 resides on chromosome 7, therefore a detailed characterization 
was carried out to investigate this chromosome in particular, and in the context of the whole 
karyotype in these cell lines. In the case of patient material, chromosome painting was carried 
out in a single colour manner specifically for chromosome 7.  
The study of human myeloid leukaemia cell lines K562 and GDM-1 revealed numerical and 
structural abnormalities involving chromosome 7. The chronic myeloid leukaemia cell line 
K562 presented tetrasomy of chromosome 7, whereas the acute myeloid leukaemia cell line 
GDM-1 carries a translocation t(6;7). Interestingly, a very complex karyotype has been 
identified in the lymphoma cell line Pfeiffer (CRL2632), but no evidence of chromosome 7 
abnormalities has emerged.  
The conventional cytogenetic technique G-banding was a useful first line investigation tool to 
screen the whole chromosomes within the cell lines. Furthermore, M-FISH technique was a 
powerful tool to identify the origin of translocated chromosomes in a 24-colour fashion.  
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In this study, FISH has enabled us to identify cryptic translocations that were misdiagnosed as 
deletions by only G-banding analysis (Chapter 3). The importance of M-FISH as a screen tool 
in detecting cryptic translocations was previously reported (Hilgenfeld et al., 2001; Mathew et 
al., 2001; Nordgren et al., 2001). 
However, there is a limitation of M-FISH technique in detecting very small balanced 
translocations; for example, in this study the der(6) was not detected by M-FISH analysis in 
the balanced translocation t(6;7 ) in the GDM-1 cell line, although  der(7) was clearly 
indicated. The der(6) was indicated by G-banding analysis in this study and by G-banding and 
FISH using specific locus probes previously (Nagel et al., 2005). This study confirmed the 
importance of using molecular cytogenetic investigations, such as M-FISH, to enable a broad 
screening of the gross chromosomal aberrations with a limitation of indicating very small 
deleted or translocated chromosomal regions. The combination of M-FISH analysis and 
classic banding techniques is required to obtain a very accurate karyotype.   
Naumann et al. (2001) successfully established a complete karyotype of the K562 cell line 
using G-banding, M-FISH, FISH (using whole chromosome painting and specific locus 
probes) and comparative genomic hybridization (CGH). Similar chromosomal abnormalities 
were reported in this study with more chromosomal abnormalities that have been detected by 
FISH using the whole chromosome painting previously. 
In the present study, the GDM-1 cell line was analysed using M-FISH technique for the first 
time. The analysis of M-FISH showed a very similar karyotype reported by G-banding 
analysis that was published previously by Nagel (Nagel el al., 2005). This finding has proven 
that G-banding is a valuable tool to detect the chromosomal abnormalities despite the 
difficulty of identifying the added genetic materials origin and the special training that is 
required for performing the analysis. 
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The GDM-1 cell line was shown previously (Nagel et al., 2005 and in this study) to carry 
t(6;7)(q23;q36) with breakpoint at 7q36, which makes it a good candidate to study HLXB9 
gene further, as it localizes at the same breakpoint.  
M-FISH was a good method to indicate general chromosomal abnormalities. Unfortunately, 
the investigation of the HLXB9 gene could not be achieved by M-FISH due to the lower 
resolution of the technique. In order to confirm the chromosomal abnormalities found by M-
FISH, further FISH investigations using a probe specific for  the HLXB9 should be carried 
out. 
6.2 Cryptic translocations revealed by FISH using WCP7 on AML patients and 
the GDM-1 cell line 
The importance of the whole chromosome painting technique was proven in the classification   
of chromosome 7 rearrangements as deletions or translocations in the AML patients and the 
GDM-1 cell line. FISH using WCP7 was a useful tool to detect cryptic unbalanced 
translocations that was reported as (del)(7q) by G-banding analysis in 3 patients.  
The powerful of the relatively simple method of whole chromosome painting in detecting 
cryptic translocations that are misdiagnosed by G-banding was reported previously (Pan et 
al., 2012; Tosi, et al., 1996 and 1997). 
The balanced chromosomal translocation t(6;7) in the GDM-1 cell line was confirmed by 
FISH using WCP7. The der(7) with the additional genetic material was clearly shown. The 
translocated part of chromosome 7 was not possible to be detected on the der(6) using WCP7, 
as the region is very small and not detected by the whole chromosome painting technique.  
However, The translocated region in der(6) was reported previously by Nagel using the G-
banding analysis and FISH using specific probes for the 6q23 and 7q36 regions (Nagel et al., 
2005). 
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In this study, the whole chromosome painting showed a limitation of the identification of the 
breakpoint by only FISH analysis. However, the use of both G-banding and FISH analysis has 
enabled us to estimate the breakpoints in these cases. 
 In order to confirm the breakpoint further FISH investigations using specific probes along the 
different regions of chromosome 7 are required. Chapter 4 focused on the use of chromosome 
painting in order to select those patients with 7q deletions and discard those patients with 
unbalanced translocations that involved the loss of the telomeric region of chromosome 7 (the 
area of interest in this study, as HLXB9 gene is localized at 7q36 very close to the telomere).  
 
6.3 Chromosomal rearrangements and HLXB9 gene expression 
The role of the homeobox gene HLXB9 in leukaemia has been investigated previously in 
numerous studies (Ballabio et al., 2009; Beverloo et al., 2001; Nagel et al., 2005; Tosi et al., 
2003; Von Bergh et al., 2006) and two main mechanisms of pathogenesis have been 
described. 
The translocation t(7;12) results in a fusion transcript  HLXB9-ETV6 in 50% of AML patients 
and over expression of HLXB9 gene was reported in all t(7;12) patients that have been 
analysed  (Ballabio et al., 2009; Von Bergh et al., 2006).    
It has been suggested that over-expression of HLXB9 in the AML cell line GDM-1, happens 
by juxtaposition with the oncogene MYB. In fact, the translocation t(6;7) in GDM-1 requires 
breakpoints at 6q23 (where MYB is located) and  at  7q36 in a region that very close to 
HLXB9 and distal to it (Nagel et al., 2005). 
To date, only two partner genes for HLXB9 have been identified. These are (i) the ETV6 gene, 
that codes for a transcription factor in the t(7;12) (q36;p13) t(7;12) (q36;p13) (Beverloo et al., 
2001; Tosi et al., 2003) and (ii) the proto oncogene MYB at 6q23 with via the t(6;7) (Nagel et 
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al., 2005). However, the involvement of MYB with HLXB9 has been so far reported only in 
the GDM-1 cell line. Further investigation is required to understand the role of MYB in this 
translocation.  
In this thesis, (Chapter 5) the role of the HLXB9 gene has been investigated in AML cell line 
(GDM-1) and 4 AML patients by FISH using a specific PAC clone containing HLXB9 gene. 
The dual FISH analysis revealed that no evidence of the HLXB9 gene structural 
rearrangements in the AML cell line and patients. The translocation breakpoint was confirmed 
to be distal to HLXB9 in the AML cell line (GDM-1). All the patients studied in chapter 4 
were characterized by the presence of an interstitial deletion of chromosome 7.In all these 
cases, the deleted region was proximal to the HLXB9 gene. This means that both proximal and 
distal breakpoint in the del(7q) did not involve HLXB9, that was retained and not deleted.    
The involvement of HLXB9 in structural rearrangements and breakage were excluded 
previously (Tosi et al., 2003; Nagel et al., 2005). Although the over-expression of HLXB9 
was reported in leukaemia patients and the GDM-1cell line (Ballabio et al., 2009; Beverloo et 
al., 2001; Nagel et al., 2005; Tosi et al., 2003; Von Bergh et al., 2006).   
Recently, in some t(7;12) patients, over-expression of HLXB9 has been reported to associate 
with nuclear changed position (Ballabio et al., 2009). The HLXB9 gene is found to be located 
towards the nuclear periphery in the absence of translocation. Interestingly, the HLXB9 allele 
on the derivative (12) is assumed to have an intermediate position towards the nuclear interior 
(Ballabio et.al, 2009). The alteration of gene position could be a mechanism that favours 
over- expression of the HLXB9 gene in t(7;12) positive AML patients. 
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6.4 Future work 
 
Currently, there is no evidence of HLXB9 gene breaks or structural rearrangements in 
leukaemia patients. However, the over expression of  HLXB9 has been recognized in AML 
patients (Tosi et al., 2003; Von Bergh et al., 2006) and cell line (GDM-1) (Nagel et al., 2005). 
The study of the HLXB9 expression in more leukaemia patients will be a valuable as these 
studies would be important to establish the real incidence of HLXB9 positive leukaemia 
cases. As some data established already an over expression of HLXB9 in very limited number 
of ALL patients and AML patients negative for t(7;12) (Ballabio et al., 2009; Von Bergh et 
al., 2006).  The characterization of HLXB9 over-expression in more leukaemia patients would 
facilitate the identification a sub-group of leukaemia patients that shared the over-expression 
of HLXB9 abnormality. This would have implications in diagnosis and prognosis and 
subsequently in therapy decisions.  
Further investigation of HLXB9 gene in patients will enable a better understanding of the 
molecular changes of gene over expression and will result in more accurate therapy targeting 
the gene being delivered to these patients.  
A position effect mechanism involving HLXB9 gene has been recently proposed in leukaemia 
patients positive for the t(7;12) (Ballabio el al., 2009). Investigations that focus on the 
HLXB9 gene position in a series of leukaemia patients involving t(7;12) and t(6;7) would be 
valuable, as this could give an indication of the changes in the nuclear architecture in 
leukaemia. Moreover, this mechanism could be a sole charge mechanism in these patients.  
It would be interesting to understand what are the consequences of the ectopic expression of 
HLXB9 gene and what the target genes are for HLXB9, being this a transcription factor. 
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Techniques of Chromatin Immuno Precipitation (ChIP) on chip are useful tools to shed some 
light on HLXB9 pathways and their alteration in cancer.  
Finally, the oncogenic potential role of the HLXB9 gene could be explored in mouse models 
to see whether an altered gene expression is sufficient to promote leukaemia development in 
animals. 
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